| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Cellectis S.A.$2.99
-0.18 (-5.77%)
D 32Pipeline Score Richly Valued Biotech · Clinical
Market Cap
257.06 M
EPS
-0.67
P/E Ratio
-
Value Trade
319.47 K
-14.84 %
Week
-12.5 %
1 Month
-11.62 %
3 Month
-27.08 %
6 Month
-78.13 %
5 Year
-91.57 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
6.13 K
52 Week Range
1.33 - 5.48
% held by Insiders
3.93 %
% held by Institutions
14.2 %
Enterprise Value
180.00 M
Total Shares
72.33 M
Short %
0.53 %
Float Shares
69.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cellectis S.A.
818Total events
18Upcoming
104Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 18
Event history 800
Jun 25, 2026
◆Quarterly UpdateCorporate
Combined General Meeting of Shareholders to approve financial statements and other resolutions
Jun 13, 2026
◆Oral PresentationUCART22Presentation
Safety and efficacy of UCART22 in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL): results of the Phase 1 BALLI-01 trial
B-cell acute lymphoblastic leukemia (B-ALL)source ↗
Jun 13, 2026
◆Poster PresentationUCART20x22Presentation
Alemtuzumab exposure and sustained IL-2 drive UCART20x22 expansion and clinical response in adults with relapsed or refractory B-cell non-Hodgkin lymphoma: NATHALI-01 study
relapsed or refractory B-cell non-Hodgkin lymphomasource ↗
Jun 11, 2026
◆Oral PresentationUCART22Presentation
Presentations available on Cellectis website
relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
Jun 11, 2026
◆Oral PresentationUCART20x22Presentation
Presentations available on Cellectis website
relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)source ↗
Jun 9, 2026
▲RMATUCART22Designation
FDA granted RMAT designation for lasme-cel
leucémie lymphoblastique aigüe à cellules B (LLA-B) en rechute ou réfractairesource ↗
Jun 9, 2026
▲Enrollment MilestoneUCART22Trial
Pivotal Phase 2 of BALLI-01 open for enrollment
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
May 13, 2026
◆Poster PresentationPresentation
Presentation of TALE-based epigenetic modulators at ASGCT annual meeting
May 12, 2026
◆AbstractUCART22Presentation
Abstract for BALLI-01 Phase 1 data published on EHA website
relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL)source ↗
May 12, 2026
◆AbstractUCART20x22Presentation
Abstract for NATHALI-01 preliminary analysis published on EHA website
relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)source ↗
May 11, 2026
◆Interim Analysiscema-celTrial
Interim pivotal data reported from ALPHA3 trial of cema-cel (n=24)
large B-cell lymphoma (LBCL)source ↗
Drug Pipeline Intelligence
D32
Pipeline Score $26M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 40%
Micro Cap (rank 548 of 911)
Percentile RankCellectis S.A. faces pipeline headwinds (32/100), with $268M risk-adjusted pipeline value, led by UCART22 in B-cell Acute Lymphoblastic Leukemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCART22 Monoclonal antibody | B-cell Acute Lymphoblastic Leukemia | Phase 1 | NCT04150497 | 20% | $117M | RECRUITING | 52 | STALLED | D (25) | Jun 30, 2026 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lasmé-cel RMAT | B-cell acute lymphoblastic leukemia | Phase 1 | 2026-06-11 | overall response rate: 100% (7/7); complete remission rate: 57% (4/7); minimal residual disease negative: 75% Read More | Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026 Read More | |
lasmé-cel RMAT | B-cell acute lymphoblastic leukemia | Phase 1 | 2026-06-11 | overall response rate: 100% (7/7); complete remission rate: 57% (4/7); minimal residual disease negative: 75% Read More | Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026 Read More | |
lasmé-cel RMAT | B-cell acute lymphoblastic leukemia | Phase 1 | 2026-06-11 | overall response rate: 100% (7/7); complete remission rate: 57% (4/7); minimal residual disease negative: 75% Read More | Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLLS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLLS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLLSCellectis Reports Results from Shareholders Meeting Held on June 25, 2026
Cellectis conducted its shareholders meeting on June 25, 2026, in Paris, where 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted, while resolution 30 was rejected. The meeting reflects strong shareholder engagement and support for the company's initiatives in gene-editing and cell therapies.
Read more →CLLSCellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Cellectis presented final Phase 1 results for lasme-cel and preliminary data for eti-cel at the EHA 2026 Congress. The BALLI-01 trial showed a 100% overall response rate in the target population for lasme-cel, while the NATHALI-01 study indicated promising results for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma. Both therapies demonstrated manageable safety profiles and are open for further patient recruitment.
Read more →CLLSCellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
Cellectis presented final Phase 1 results for lasmécel and preliminary data for éti-cel at the EHA 2026 congress. The BALLI-01 trial showed a 100% overall response rate in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The safety profile was satisfactory, with manageable adverse events. The ongoing Phase 2 trial is now open for patient recruitment.
Read more →CLLSCellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire
Cellectis has been granted RMAT designation by the FDA for lasmecabtagene timgedleucel (lasm-cel), a CAR-T therapy targeting CD22 for relapsed or refractory B-ALL patients. This designation highlights the therapy's potential to address unmet medical needs. Promising phase 1 data supports its efficacy, while the ongoing phase 2 trial is currently recruiting patients.
Read more →CLLSCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Cellectis announced that the FDA has granted RMAT designation to its allogeneic CAR-T therapy, lasme-cel, for treating relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This designation highlights the therapy's potential to meet significant medical needs. Phase 1 data showed promising results, and the pivotal Phase 2 trial is now open for enrollment.
Read more →CLLSCELLECTIS A corporation (“SA”) with a share capital of 5,029,549.70 euros Registered office : 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “ Company ”)
Cellectis SA has announced a combined general meeting scheduled for June 25, 2026, to discuss several key items, including the approval of the annual financial statements for 2025. During this period, the company experienced a substantial loss of 61,849,605 euros. The meeting will also address various authorizations for share capital increases and the renewal of several board members. Investors may need to consider the implications of these financial challenges and potential dilution of shares caused by ongoing capital management proposals.
Read more →CLLSL’Assemblée Générale Mixte de Cellectis se tiendra le le 25 juin 2026
Cellectis has announced its mixed general assembly scheduled for June 25, 2026, at 14:30 Paris time. The meeting will take place at the Biopark auditorium in Paris. This event highlights Cellectis' ongoing commitment to engaging with its shareholders while advancing its pioneering genome editing platform.
Read more →CLLSCellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Cellectis has announced its annual general meeting scheduled for June 25, 2026, in Paris. The meeting will take place at the Biopark auditorium at 2:30 p.m. CET. This event reflects the company's commitment to transparency and governance as it continues to develop innovative gene-editing therapies.
Read more →CLLSCellectis Reports Financial Results for the First Quarter 2026
Cellectis reported its financial results for Q1 2026, highlighting a cash position of $188 million. The company is advancing its pivotal Phase 2 trial for lasme-cel in relapsed or refractory B-ALL and expects to present full Phase 1 data for eti-cel in relapsed or refractory NHL in Q4 2026. Despite a decrease in revenues and an increase in R&D expenses, interim data from Allogene's cema-cel trial offers validation for Cellectis' approach to CAR-T therapies.
Read more →CLLSCellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Cellectis announced it will present clinical data on lasme-cel and eti-cel at the EHA 2026 Annual Congress. The BALLI-01 trial data for lasme-cel, a CAR-T therapy for relapsed B-ALL, shows promising safety and efficacy, while the NATHALI-01 trial for eti-cel in B-NHL will provide insights into treatment optimization. Both trials are pivotal for future developments.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three month period ended
Cellectis S.A. has released its unaudited condensed consolidated financial statements for the quarter ended March 31, 2026. The report indicates a decrease in total assets and a substantial net loss compared to the previous quarter. Total revenues and other income have also significantly dropped while operating expenses have increased. Furthermore, the report includes forward-looking statements which carry inherent risks and uncertainties that could affect the company's future performance.
Read more →CLLS▼ -6.3%on this news
Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026
Cellectis, a clinical-stage biotechnology company, will announce its Q1 financial results on May 11, 2026. The results will be available after market closure in the U.S. Unlike typical practices, the company will not hold a conference call for this announcement. Cellectis focuses on developing innovative cell and gene therapies for serious diseases.
Read more →CLLS▼ -6.3%on this news
Cellectis to Report First Quarter Financial Results on May 11, 2026
Cellectis has announced it will report its financial results for the first quarter of 2026 on May 11, 2026, after the US market closes. The company will not hold a conference call to discuss these results, but its investor relations team is available for inquiries. Cellectis specializes in gene-editing technologies for cell and gene therapies.
Read more →CLLSCellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Cellectis showcased its TALE-based epigenetic editing platform at the ASGCT annual meeting. This innovative approach allows for gene regulation without altering DNA, presenting a safer alternative to traditional methods. The research demonstrated over 90% reduction in gene activity for specific targets, highlighting the effectiveness of their high-throughput screening system. The findings contribute to the expanding gene editing toolbox for therapeutic applications.
Read more →CLLSCellectis présente sa plateforme d’édition épigénétique pour éteindre des gènes sans modifier l’ADN, lors du congrès annuel de l’ASGCT
Cellectis has introduced a pioneering epigenetic editing platform at the ASGCT annual meeting. This approach utilizes TALE-based modulators to achieve significant gene knockdown without altering DNA sequences. The research demonstrated over 90% reduction in gene activity in T-cells and hepatocytes, showcasing the platform's potential for safer gene regulation.
Read more →CLLSCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
Cellectis highlights positive interim data from Allogene's pivotal ALPHA3 trial of cema-cel for large B-cell lymphoma. The trial showed a significant difference in minimal residual disease (MRD) negativity between the treatment and observation arms. The treatment was well-tolerated with no serious adverse events reported. Cellectis anticipates further developments in the trial, with potential for a Biologics License Application submission if results remain positive.
Read more →CLLS▲ +19.2%on this newsshared move
Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis
Cellectis announced positive interim results from the ALPHA3 trial evaluating cema-cel for treating large B-cell lymphoma. The treatment demonstrated a 58.3% negative minimal residual disease (MRD) rate compared to 16.7% in the observation group. Cema-cel was well tolerated, with no severe adverse events reported. The trial's success could lead to a market approval application.
Read more →CLLSCellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Cellectis reported its financial results for 2025, highlighting significant progress in its clinical trials, particularly with lasme-cel, which achieved a 100% response rate in its Phase 2 study. The company anticipates submitting a Biologics License Application in 2028, marking a pivotal moment for its CAR-T therapies. However, it also faced increased operational costs and a notable financial loss compared to the previous year.
Read more →CLLSCellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
Cellectis has released its financial results for Q4 2025 and provided updates on its clinical activities. The company is currently conducting a pivotal Phase 2 trial for lasmé-cel in relapsed or refractory B-cell acute lymphoblastic leukemia, with promising results showing 100% overall response rate in the target population. Cellectis also reported a net loss of $67.6 million for the fiscal year 2025, but has sufficient cash reserves projected until mid-2027. The next interim analysis for the Phase 2 trial is expected in Q4 2026.
Read more →CLLSCellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Cellectis has announced the date for its financial results report for Q4 and full year 2025, set for March 19, 2026. Following the report, an investor conference call will take place on March 20, 2026, to discuss the results and provide updates on business activities. Cellectis is known for its pioneering work in gene-editing and CAR T immunotherapies.
Read more →CLLSCellectis Announces 2026 Strategy and Catalysts
Cellectis has outlined its strategic priorities for 2026, focusing on the pivotal Phase 2 trial for lasme-cel in acute lymphoblastic leukemia (ALL). The company anticipates interim data in Q4 2026 and aims to leverage partnerships with AstraZeneca. Cellectis is committed to advancing its allogeneic CAR-T pipeline amidst potential regulatory challenges.
Read more →CLLS▼ -15.2%on this news
Cellectis Announces Arbitral Decision in Dispute with Servier
Cellectis announced that an Arbitral Tribunal has issued a decision in its arbitration with Servier, resulting in a partial termination of their License Agreement concerning product UCART19 V1. The Tribunal's ruling allows Cellectis to engage in discussions for a direct license at Allogene's request. All other claims from both parties were dismissed.
Read more →CLLS▼ -15.2%on this news
Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier
Cellectis announced that an arbitration tribunal has made a decision in its dispute with Servier regarding a licensing agreement. The tribunal partially terminated the contract for UCART19 V1 and requested Cellectis to negotiate in good faith with Allogene for a direct license. All other claims from both parties were dismissed.
Read more →CLLSASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Cellectis presented promising data on its eti-cel therapy for relapsed/refractory non-Hodgkin lymphoma at the ASH 2025 meeting. The Phase 1 NATHALI-01 trial showed an overall response rate of 88% and a complete response rate of 63%. The company aims to enhance these results by investigating the effects of low dose IL-2 support. Full data is expected in 2026.
Read more →CLLSASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire
Cellectis presented encouraging preliminary data from the Phase 1 NATHALI-01 trial at the ASH 2025 conference. The trial evaluates the candidate drug éti-cel, showing an overall response rate of 88% and a complete response rate of 63% in patients with relapsed or refractory non-Hodgkin lymphoma. The company plans to explore the impact of adding low-dose interleukin-2 to enhance treatment efficacy.
Read more →CLLSCellectis organise un webinaire dédié aux actionnaires français le jeudi 4 décembre 2025
Cellectis will hold a webinar on December 4, 2025, to present promising clinical data for lasmécel, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia. The session will cover the pivotal Phase 2 trial design and potential commercial prospects. Additionally, updates on the eticel program for non-Hodgkin lymphoma will be shared.
Read more →CLLS▲ +7.1%on this news· ran to +30% by day 3
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
Cellectis has published an article in Nature Communications detailing a non-viral gene editing process that uses circular single-stranded DNA (CssDNA) for efficient gene insertion in hematopoietic stem cells (HSPCs). This new method significantly improves knock-in efficiency compared to traditional viral vectors, enabling the insertion of large genetic sequences and demonstrating better engraftment in murine models. The findings highlight a promising advancement in the development of next-generation cell and gene therapies, positioning Cellectis as a key player in the gene-editing field.
Read more →CLLS▲ +11.3%on this news
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Cellectis reported its third-quarter 2025 financial results, showcasing promising data from its lasme-cel and eti-cel programs for treating r/r B-ALL and r/r NHL. The company has a solid cash position of $225 million, expected to sustain operations into H2 2027. Upcoming milestones include an update at the ASH 2025 Annual Meeting and an interim analysis for the pivotal Phase 2 BALLI-01 trial in Q4 2026.
Read more →CLLS▲ +11.3%on this news
Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mise à jour de ses activités
Cellectis has announced its third-quarter 2025 financial results and provided updates on its clinical activities. The company reports promising data from its candidates lasm -cel and 9ti-cel, which are in clinical trials for acute lymphoblastic leukemia and non-Hodgkin lymphoma, respectively. Cellectis anticipates submitting a market authorization application for lasm -cel in 2028, supported by a strong financial position. However, the company recorded a net loss of $41.3 million for the period.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the nine month period ended
Cellectis S.A. released its unaudited condensed consolidated financial statements for the nine-month period ending September 30, 2025. The report indicates a significant increase in total revenues from $34,052,000 to $67,386,000, suggesting improved business activity. However, the net income loss also rose from $36,761,000 to $41,275,000, highlighting continued financial challenges. Additionally, total liabilities saw a minor decrease, which may reflect ongoing financial management efforts amid risks outlined in their forward-looking statements.
Read more →CLLS▼ -5.2%on this news
Cellectis to Present a Development Update for eti-cel at ASH 2025
Cellectis announced the acceptance of two abstracts for presentation at the ASH 2025 meeting. The first poster details a development update on eti-cel, showing promising preliminary results in patients with relapsed/refractory non-Hodgkin lymphoma. The second poster discusses the correlation between alemtuzumab exposure and response in patients treated with lasme-cel for acute lymphoblastic leukemia. Full Phase 1 data for eti-cel will be presented in 2026.
Read more →CLLS▼ -5.2%on this news
Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès annuel de l’ASH 2025
Cellectis announced that two abstracts will be presented at the ASH 2025 annual congress. The first poster will detail advancements in the CAR-T therapy eti-cel, showing an encouraging overall response rate of 86% in patients with relapsed or refractory non-Hodgkin lymphoma. The second poster will explore the correlation between alemtuzumab exposure and response rates in patients treated with lasmé-cel. Full Phase 1 data for eti-cel is expected in 2026.
Read more →CLLS▼ -5.2%on this newsshared move
Cellectis publiera ses résultats financiers du troisième trimestre le 7 novembre 2025
Cellectis will release its financial results for the third quarter ending September 30, 2025, on November 7, 2025, after market close in the U.S. The press release will be available on their investor website. Notably, Cellectis will not hold a conference call to discuss the results.
Read more →CLLSCellectis to Report Third Quarter Financial Results on November 7, 2025
Cellectis, a clinical-stage biotechnology company, announced it will report its third quarter financial results for 2025 on November 7. The results will be available after the market closes, and no conference call will be held to discuss them. Cellectis is recognized for its innovative CAR T-cell therapies and gene editing platforms aimed at treating cancer and potentially other diseases. The company's operations span multiple locations, including Paris, New York, and Raleigh.
Read more →CLLSLe R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
Cellectis recently hosted a R&D Day highlighting promising clinical data for lasm -cel (UCART22) in treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The Phase 1 trial showed a 68% overall response rate, with 100% of patients in the target group becoming eligible for transplant. The company is advancing to a pivotal Phase 2 study, aiming for a market submission by 2028.
Read more →CLLSCellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Cellectis hosted an R&D Day to present promising data on lasme-cel, a therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The Phase 1 BALLI-01 study indicated a high overall response rate and safety profile, with plans for a pivotal Phase 2 trial. The company estimates significant commercial potential for lasme-cel, projecting peak sales of up to $700 million.
Read more →CLLS▲ +10%on this newsshared move
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Cellectis is hosting an R&D Day in New York City to showcase its pipeline progress, specifically the full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL). The event features insights from the company's leadership and key opinion leaders in the field. While the company highlights significant advancements and opportunities in gene editing and CAR T therapies, there are also potential risks concerning regulatory approvals and validation of clinical trial data. Cellectis is noted for its unique position as a pioneer with comprehensive manufacturing capabilities in the gene therapy landscape.
Read more →CLLS▲ +10%on this newsshared move
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL o Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the t
Cellectis hosted its R&D Day, showcasing the potential of lasme-cel in addressing unmet needs for patients with relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL). Efficacy data indicated an overall response rate of 68%, with 100% of patients in the targeted Phase 2 becoming transplant eligible. Lasme-cel has demonstrated a generally well-tolerated safety profile, with manageable adverse events recorded during the Phase 1 study. The company anticipates initiating a pivotal Phase 2 trial by the end of 2025 and has outlined a strategic registration path for lasme-cel.
Read more →CLLS▼ -5.7%on this newsshared move
PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the six month period ended
Cellectis S.A. released its unaudited condensed consolidated financial statements for the six months ending June 30, 2025. The report shows a substantial revenue increase from $16,002 in 2024 to $30,222 in 2025, despite reporting a growing net loss, which rose from $36,761 to $41,863. The total shareholders' equity has decreased, highlighting potential financial challenges. While cash and cash equivalents declined, non-current financial assets remain strong, indicating ongoing financial efforts despite losses.
Read more →CLLS▲ +8.2%on this news· ran to +22% by day 1
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
Cellectis announced that it will present its latest findings on non-viral gene therapy and TALE base editors at the ESGCT Annual Congress in Sevilla, Spain, from October 7-10, 2025. The data highlights the success of circular single-stranded DNA (CssDNA) as a highly efficient universal template for gene therapy, particularly in hematopoietic stem cells. Additionally, the study on TALE base editors emphasizes their potential for precise genome editing with minimized off-target effects. These presentations underscore Cellectis's commitment to advancing innovative gene-editing technologies.
Read more →CLLSCellectis Reports Second Quarter 2025 Financial Results & Business Updates
Cellectis has reported its financial results for the second quarter of 2025 and plans to host an Investor R&D Day on October 16, 2025, in New York City. Key updates include the successful completion of end-of-Phase 1 discussions with FDA and EMA for its drug candidate lasme-cel (UCART22), with a pivotal Phase 2 trial anticipated in the latter half of the year. The company has also appointed Andr e Muller to its Board of Directors. Financially, Cellectis ended June 30, 2025, with $230 million in cash reserves, providing operational support through H2 2027.
Read more →CLLS▲ +13.1%on this news
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
Cellectis has announced the date for its financial report for the second quarter of 2025, which will be released on August 4, 2025, after the US market closes. Following this release, there will be an investor conference call on August 5, 2025, to discuss the results and provide an update on business activities. The company specializes in gene editing and cell therapy, and is noted for its off-the-shelf CAR T therapies. Cellectis operates from multiple locations including Paris, New York, and Raleigh.
Read more →CLLSCELLECTIS
Cellectis held its annual shareholders meeting, during which all ordinary and extraordinary resolutions were overwhelmingly approved by shareholders. Significant resolutions included the approval of financial statements for the fiscal year ended December 31, 2024, and various authorizations for capital increases and share buybacks. The shareholder vote demonstrated strong support, with most resolutions passing with over 99% approval. This suggests robust confidence in the company’s strategic direction and governance.
Read more →CLLSCellectis Reports Results from Shareholders Meeting Held on June 26, 2025
Cellectis held a shareholders meeting on June 26, 2025, where a majority of resolutions, including the appointment of Andr Muller to the Board of Directors, were approved. The meeting confirmed the expiration of Mr. Axel-Sven Malkomes' term and Mr. Pierre Bastid's resignation. The company aims to leverage its gene-editing platform for developing innovative gene therapies, underscoring its mission in the biopharma sector.
Read more →CLLSCELLECTIS A corporation (“SA”) with a share capital of 5,014,561.35 euros Registered office: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the “ Company ”)
Cellectis is holding a combined general meeting of shareholders on June 26, 2025, to discuss various agenda items including the approval of annual and consolidated financial statements for the year ended December 31, 2024. During this financial year, the company recorded a loss of €58.2 million. The meeting will also cover the appointment of a new director, share buyback authorization, and other capital-related resolutions. Furthermore, there has been no dividend distribution for the last three financial years.
Read more →CLLSCellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
Cellectis announced that it will hold its annual general meeting on June 26, 2025, at the Biopark auditorium in Paris. The meeting will cover the detailed agenda and participation modalities, which are available on Cellectis' website. As a clinical-stage biotechnology firm, Cellectis is focused on developing pioneering cell and gene therapies, particularly using its gene-editing platform for CAR T immunotherapies.
Read more →CLLSCellectis Reports Financial Results for the First Quarter 2025
Cellectis reported its financial results for Q1 2025, highlighting a net loss of $18.1 million compared to a net income in the previous year. The company maintains a strong cash position of $246 million to fund ongoing clinical trials, particularly in the development of UCART22 and UCART20x22. Additionally, Cellectis is advancing research in non-viral gene editing and has ongoing collaborations with AstraZeneca for various CAR T programs. The company is set to present new research at the ASGCT annual meeting in May 2025.
Read more →CLLSCellectis to Report First Quarter Financial Results on May 12, 2025
Cellectis, a clinical-stage biotechnology company specializing in gene editing, announced it will report its financial results for the first quarter of 2025 on May 12, 2025, after the US market closes. The company focuses on developing innovative CAR T for oncology and has in-house manufacturing capabilities. Despite the lack of a conference call to discuss the results, Cellectis emphasizes its commitment to advancing life-saving cell and gene therapies.
Read more →CLLSCellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Cellectis unveiled new research at the ASGCT annual meeting, focusing on TALEN-mediated non-viral transgene insertion and advancements in TALE base editing. These innovative techniques aim to provide safer, more efficient gene therapy options for various diseases, addressing limitations associated with traditional viral methods. The findings suggest potential for enhancing gene insertion efficacy and improving cellular health, setting the foundation for next-generation therapies. Cellectis continues to position itself as a leader in gene editing, with plans to share findings publicly during the meeting.
Read more →CLLSCellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Cellectis has reported its financial results for Q4 and the full year 2024, highlighting significant developments in its UCART programs. The company has received Orphan Drug Designations for UCART22 and announced an expansion of its partnership with AstraZeneca, which includes multiple allogeneic CAR T initiatives. With a solid cash position of $264 million, Cellectis plans to focus on advancing its clinical trials and innovative gene therapies, while prioritizing enrollment for key studies aimed at treating relapsed or refractory cancers. Future updates are anticipated for late 2025, as the company continues to push forward in its mission to address critical patient needs.
Read more →CLLSCellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Cellectis has announced that it will report its financial results for the fourth quarter and full year of 2024 on March 13, 2025. Following the release, an investor conference call and webcast will be held on March 14, 2025, to discuss the results and provide updates on business activities. As a clinical-stage biotechnology company, Cellectis utilizes an allogeneic approach in CAR T immunotherapies, with capabilities from gene editing to product manufacturing.
Read more →CLLSCellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Cellectis presented its 'Smart CAR T' strategy at the AACR-IO 2025, highlighting a novel approach to enhance CAR T cell efficacy specifically against solid tumors. This strategy, which employs TALEN gene-editing technology, aims to utilize a CAR-inducible IL-2 variant to boost anti-tumor activity while minimizing systemic toxicity. The presentation showcased positive in vitro and in vivo results, indicating a promising advancement in cancer immunotherapy.
Read more →CLLSCellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis has announced the drawdown of the final €5 million tranche under its €40 million credit facility agreement with the European Investment Bank. This completes the full funding under the agreement, with proceeds allocated towards the development of its CAR T-cell product candidates. Each warrant issued to the EIB permits subscription for ordinary shares at €1.70, reflecting current market pricing. The full financing supports Cellectis' ongoing efforts in advancing innovative gene-editing technologies and therapies for cancer treatment.
Read more →CLLSCellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis announced that it will present pre-clinical data at the upcoming SITC Annual Meeting aimed at enhancing CAR T-cell activity against solid tumors while mitigating toxicity risks. The presentation will feature strategies utilizing TALEN gene editing for creating allogeneic CAR T-cells, which focus on overcoming the immunosuppressive barriers present in tumor microenvironments. By targeting specific pathways, Cellectis aims to improve the efficacy and safety profile of CAR T-cell therapies for solid malignancies.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine month periods ended
Cellectis S.A. has released its unaudited condensed consolidated financial statements for the three and nine month periods ending September 30, 2024. The report shows a significant increase in both total current assets and current financial assets. However, the company is facing a widening loss in net income and an increasing retained earnings deficit. These financial results are presented in accordance with International Accounting Standard 34 and include various forward-looking statements subject to uncertainties.
Read more →CLLSCellectis Provides Business Updates and Financial Results for Third Quarter 2024
Cellectis has disclosed its third quarter 2024 business updates, highlighting ongoing enrollment in its clinical trials for UCART22 and UCART20x22, with key dataset presentations expected in 2025. The company remains buoyant due to its collaboration with AstraZeneca on several cell and gene therapy programs. Additionally, Cellectis has appointed Dr. Adrian Kilcoyne as Chief Medical Officer, bringing in crucial industry expertise. A significant cash position of $264 million sets a solid foundation for future developments despite some deprioritization in its portfolio.
Read more →CLLSCellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis, a clinical-stage biotechnology company, announced it will report its financial results for the third quarter of 2024 on November 4, 2024. Following the results announcement, an investor conference call and webcast will take place on November 5, 2024, providing updates on business activities. Cellectis is recognized for its pioneering gene-editing platform, focusing on developing cell and gene therapies utilizing CAR-T immunotherapy for cancer treatment.
Read more →CLLSCellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Cellectis will present pre-clinical data on TALE base editors and non-viral gene therapy techniques at the ESGCT's 31st Annual Congress, held in Roma, Italy from October 22-25, 2024. The presentations will cover advancements in TALEB technology and efficient gene insertion processes in hematopoietic stem cells. These findings are part of Cellectis' ongoing efforts to develop innovative gene therapies to treat various diseases. The posters will be available on Cellectis' website following the presentations.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six month periods ended
Cellectis S.A. has released its unaudited interim consolidated financial statements for the period ending June 30, 2024. These statements were prepared in accordance with International Accounting Standard 34 and show total assets increased from December 2023 to June 2024. While there are positive trends in current financial assets and cash reserves, the report notes several risks that could affect future performance, including a substantial retained earnings deficit.
Read more →CLLS▼ -5.8%on this news
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis has presented promising pre-clinical evidence indicating that TALEN-edited MUC1 CAR T-cells may serve as a viable treatment for advanced-stage triple-negative breast cancer (TNBC). This study highlights the potential of multi-armored CAR T-cells to improve response rates against tumors, while also demonstrating a reduction in required dosages through intratumoral injections. The findings suggest that the engineered CAR T-cells can effectively target both local and distant tumors, providing hope for patients with limited therapeutic options in managing aggressive TNBC.
Read more →CLLSCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis has published a new article in Molecular Therapy describing a novel SMART DUAL CAR T-cell approach utilizing TALEN-mediated gene editing. This technique is designed to effectively target challenging recalcitrant solid tumors while minimizing safety risks related to off-tumor toxicity. The innovative strategy involves two CAR constructions, which enhance T-cell infiltration into tumors and address common barriers faced in solid tumor treatment. The implications of this research could pave the way for more effective cancer therapies using CAR T-cells.
Read more →CLLSCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Cellectis has appointed Dr. Adrian Kilcoyne as its new Chief Medical Officer, effective immediately. Dr. Kilcoyne brings extensive experience in oncology and has previously held key positions in other biopharma companies. His appointment is seen as a strategic move to advance Cellectis' product pipeline for CAR-T therapies. Additionally, the company expresses gratitude to departing CMO Dr. Mark Frattini for his contributions.
Read more →CLLSCellectis Provides Financial Results for the Second Quarter 2024
Cellectis has reported its second quarter financial results for 2024, noting significant progress in its clinical programs, including Orphan Drug Designations for UCART22 and CLLS52. The company's cash position stood at $273 million, indicating a robust financial state that supports its ongoing research initiatives. Additionally, a substantial investment from AstraZeneca strengthens its position in the biotech landscape. Efforts to enroll patients in clinical trials for potential life-saving treatments continue as Cellectis aims for advancements in its pipeline by the end of the year.
Read more →CLLSCellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Cellectis held its annual shareholders meeting on June 28, 2024, where around 40% of shares were exercised. During the meeting, resolutions 1 through 28 were adopted, while resolution 29 was rejected, aligning with management's recommendations. This outcome reflects shareholder trust in the company's direction and its ongoing efforts in developing cell and gene therapies. More detailed voting results can be found on Cellectis' official website.
Read more →CLLSCELLECTIS ANNUAL SHAREHOLDERS MEETING June 28. 2024 VOTE RESULTS Ordinary Resolutions NB Resolution Result For Against Vote whithhold Total votes Shares represented by the votes cast Percentage of the share capital repre
Cellectis held its annual shareholders meeting on June 28, 2024, where all proposed ordinary and extraordinary resolutions were overwhelmingly approved. The financial statements for the year ending December 31, 2023, received near-unanimous support from shareholders. Noteworthy approvals included the delegation of authority for potential capital increases and the renewal of board members, indicating confidence in the company's direction and governance. The meeting illustrated strong shareholder engagement and a commitment to future growth initiatives.
Read more →CLLSCellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
Cellectis has published a manuscript in Scientific Reports detailing three crucial factors that can enhance the efficiency of TALE base editing. The study emphasizes the importance of spacer length, TALEB architecture, and the composition of surrounding bases in achieving better editing outcomes. This research is a significant step forward in advancing the use of TALE editors for potential therapeutic applications, offering insights that could improve gene editing strategies in the future.
Read more →CLLSCellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis has published a significant study in Nature Communications regarding a non-viral gene therapy approach for sickle cell disease (SCD). Utilizing TALEN technology, the therapy facilitates efficient correction of the HBB gene in hematopoietic stem and progenitor cells. The research shows over 50% expression of normal adult hemoglobin in edited cells, suggesting therapeutic potential. These advancements prepare Cellectis for future therapeutic applications aimed at addressing SCD and possibly other genetic disorders.
Read more →CLLSCellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
Cellectis has received Orphan Drug Designation from the European Commission for its allogeneic CAR T product candidate UCART22, aimed at treating Acute Lymphoblastic Leukemia (ALL). This designation recognizes the significant potential of UCART22, especially for patients with few treatment options. Early clinical data reported a 67% response rate in a specific patient cohort, further supporting its development. The company plans to provide updates on its ongoing trial, BALLI-01, by the end of 2024.
Read more →CLLSCellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
Cellectis, a clinical-stage biotechnology company, has announced that its annual general meeting will take place on June 28, 2024, in Paris, France. The meeting will provide insights into the company's ongoing efforts in developing life-saving cell and gene therapies utilizing its gene-editing platform. Cellectis aims to revolutionize cancer treatment with off-the-shelf CAR-T immunotherapies and novel gene editing approaches, highlighting its long-standing expertise in the field.
Read more →CLLSCellectis Reports Financial Results for First Quarter 2024
Cellectis reported its financial results for the first quarter of 2024, highlighting a significant $140 million equity investment from AstraZeneca, which bolsters its cash position. The company’s cash reserves are projected to sustain operations into 2026, allowing continued focus on advancing its clinical trials for gene therapies. Additionally, Cellectis reported a notable revenue increase compared to the previous year, demonstrating growth in its business activities. The company is actively engaged in its ongoing studies targeting various types of blood cancers and is set to provide updates later in 2024.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month periods ended
Cellectis S.A. published its unaudited interim consolidated financial statements for the three months ending March 31, 2024. The report reveals a significant increase in revenues, growing from $139,000 in the same period last year to $4.5 million. However, the company experienced a substantial increase in net loss, which deepened from $101.1 million to $405.8 million. Despite these challenges, total shareholders' equity rose slightly, indicating some financial stability.
Read more →CLLSCellectis to Report First Quarter 2024 Financial Results on May 28, 2024
Cellectis, a clinical-stage biotechnology company, is set to release its financial results for the first quarter of 2024 on May 28, 2024. Following this, an investor conference call will be held on May 29, 2024, to discuss these results and provide updates on business activities. Cellectis specializes in gene-editing technology aimed at developing cell and gene therapies for various diseases, primarily focusing on CAR-T immunotherapies in oncology. The report will reflect the company's ongoing efforts to address unmet medical needs through innovative treatments.
Read more →CLLSCELLECTIS A corporation ( SA ) with a share capital of 4,997,776.75 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the Company ) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHO
Cellectis S.A. will hold a combined general meeting on June 28, 2024, in Paris to discuss important agenda items including the approval of annual financial statements. The company reported substantial losses of over 104 million euros and approximately 108 million USD for the year ending December 31, 2023. Additionally, the retained earnings account is expected to be negative, with no dividends distributed in the last three years. Key appointments and financial agreements with Bpifrance will also be addressed during the meeting.
Read more →CLLS▲ +12%on this news
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Cellectis has announced the successful completion of a $140 million equity investment by AstraZeneca, following necessary regulatory clearances. This investment, comprising 10 million 'class A' and 18 million 'class B' convertible preferred shares, grants AstraZeneca substantial ownership and influence within the company. Additionally, the appointment of two new board members is now effective, suggesting a collaborative effort to drive strategic initiatives. This funding underscores AstraZeneca's commitment to Cellectis' innovative gene-editing capabilities.
Read more →CLLS▲ +17.9%on this newsshared move
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Cellectis has announced the appointment of Arthur Stril as the interim Chief Financial Officer, following the resignation of Bing Wang. Mr. Stril, who joined Cellectis in 2018, has previously held positions as Vice President of Corporate Development and Chief Business Officer, indicating a strong internal leadership transition. His appointment comes at a pivotal time as Cellectis is set to advance its critical pipeline for cell and gene therapies targeting hard-to-treat cancers. The company expresses optimism for future growth and continued execution in its clinical trials and strategic partnerships.
Read more →CLLS▲ +17.9%on this newsshared move
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer New York, NY
Cellectis has appointed Arthur Stril as interim Chief Financial Officer following the resignation of Bing Wang. Stril, who has been with Cellectis since 2018 and previously served as Chief Business Officer, will oversee finance and investor relations while continuing his role in business development. The company expresses confidence in Stril's capabilities to advance its clinical trials and partnerships in the cell and gene therapy sector as it focuses on addressing unmet medical needs in cancer treatment. Cellectis emphasizes its ongoing commitment to innovation and excellence during this transition.
Read more →CLLSCellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Cellectis has reported its financial results for Q4 and full year 2023, highlighting promising preliminary data from ongoing Phase 1 clinical trials. Key developments include the strategic collaboration with AstraZeneca aimed at enhancing cell and gene therapies, as well as a solid cash position of $156 million. The company shared positive interim results for its product candidates, UCART22 and UCART20x22, at the recent ASH Annual Meeting, indicating a high response rate and manufacturing enhancements. Cellectis continues to focus on its innovative gene editing platform and clinical study advancements.
Read more →CLLSCellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis has introduced innovative TALEN editing processes for gene correction and insertion in hematopoietic stem and progenitor cells (HSPCs). This approach, which utilizes non-viral circular single strand DNA delivery, demonstrates significant advancements in gene therapy efficiency without affecting cell integrity. The data reveal the potential to deliver therapeutic proteins that can cross the blood-brain barrier, addressing a critical challenge in treating neurological disorders. Presentations at the American Society of Gene and Cell Therapy will outline these novel findings and their implications for future therapies.
Read more →CLLSCellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis has published a new research paper in Molecular Therapy detailing a TALEN-mediated intron editing approach that enhances the delivery of therapeutics to the brain. This innovative method allows hematopoietic stem and progenitor cells (HSPCs) to express the enzyme IDUA specifically within the myeloid lineage, potentially paving the way for therapies targeting inborn metabolic diseases and neurological disorders. The study highlights the efficient engraftment of edited HSPCs in bone marrow and their ability to cross the blood-brain barrier, which could transform treatment options for patients.
Read more →CLLSCellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Cellectis announced two poster presentations highlighting advancements in a novel TALEN® editing process for gene correction and insertion in hematopoietic stem and progenitor cells (HSPCs). These findings will be presented at the ASGCT Annual Meeting scheduled for May 2024. The presentations showcase innovative approaches aimed at improving gene therapy techniques, with potential implications for long-term treatment strategies in various diseases. Cellectis continues to develop its gene-editing platform to transform patient care in hematologic therapies.
Read more →CLLSCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis announced the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank. The funds will support the development of its allogeneic CAR T-cell product candidates. As part of the agreement, Cellectis issued over 1.46 million warrants to the EIB, allowing them to subscribe to ordinary shares at €2.53 each. The financing arrangement underscores the company's ongoing commitment to advancing its gene-editing technologies in oncology.
Read more →CLLSCellectis Reports Results from Shareholders Meeting Held on December 22, 2023
Cellectis held a shareholders meeting on December 22, 2023, where significant resolutions were passed, including the adoption of a $140 million investment from AstraZeneca. Shareholders also approved the appointments of two new directors, Mr. Marc Dunoyer and Dr. Tyrell Rivers, both with extensive experience in the pharma industry. However, one resolution was rejected, and the investment's completion is contingent on regulatory approvals, which may pose challenges. Overall, the meeting showcased strong shareholder support for the company's future initiatives in life-saving therapies.
Read more →CLLSCELLECTIS Shareholders Meeting
During a shareholders meeting on December 22, 2023, CELLECTIS approved the creation of two new classes of preferred shares, Class A and Class B, with significant shareholder backing. The board was delegated authority to increase share capital by issuing these new shares, which reflects a proactive approach to capital management. Additionally, two new directors were appointed, suggesting an effort to strengthen leadership. However, a proposal for a company savings plan was not approved by shareholders, indicating some dissent in certain areas.
Read more →CLLS▲ +11.5%on this news
Time Sensitive Materials Depositary s Notice of Combined Ordinary and Extraordinary General Meeting of Cellectis S.A. ADSs: American Depositary Shares ( ADSs ). ADS CUSIP No.: 15117K103. ADS Record Date
Cellectis S.A. has announced a Combined Ordinary and Extraordinary General Meeting for holders of its American Depositary Shares (ADSs) to take place on December 22, 2023. The notice specifies that ADS holders must be recorded as of November 28, 2023, for voting eligibility. Voting instructions must be submitted by December 18, 2023. The meeting will cover outlined agendas available on the company's website.
Read more →CLLS▲ +11.8%on this news
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Cellectis announced it will hold a general meeting for shareholders on December 22, 2023, at the Biopark auditorium in Paris. The agenda and resolutions for the meeting have been published online, showcasing the company's commitment to transparency with its investors. Cellectis is recognized for its pioneering gene-editing technology aimed at developing cell and gene therapies. This meeting could potentially influence its shareholder relations and future growth strategies.
Read more →CLLS▲ +11.8%on this news
English language translation For information purpose only CELLECTIS French soci t anonyme with share capital of EUR 3,587,560.05 Registered office: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 R.C.S. Paris (the Com
Cellectis has announced a combined extraordinary and ordinary general meeting scheduled for December 22, 2023, to discuss the creation of new classes of preferred shares, specifically Class A and Class B, which are convertible into ordinary shares. The meeting will address amendments to the company’s bylaws concerning the rights and characteristics of these new shares, including conditions under which they may convert. Shareholders will also be required to waive their preferential subscription rights for the new ordinary shares resulting from this conversion. The issuance of these preferred shares may impact existing shareholders by potentially diluting their shareholdings.
Read more →CLLS▲ +9.4%on this news· ran to +21% by day 3shared move
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
Cellectis has finalized a Subsequent Investment Agreement with AstraZeneca for a $140 million equity investment, initially announced on November 1, 2023. The deal involves the issuance of 28 million convertible preferred shares, with AstraZeneca expected to hold approximately 44% of Cellectis' share capital following the investment. An extraordinary shareholders' meeting is set for or around December 22, 2023, to approve the investment, which is also contingent upon clearance from the French Ministry of Economy among other conditions. Despite this positive development, the investment's completion is dependent on meeting shareholder and regulatory requirements.
Read more →CLLSCellectis Reports Financial Results for Third Quarter and First Nine Months 2023
Cellectis reported financial results for the third quarter and first nine months of 2023, highlighting a strategic collaboration with AstraZeneca that includes a $25 million upfront payment and potential total investments of $225 million. The company announced updates on ongoing clinical trials for its UCART products targeting various blood cancers, with promising preliminary results from studies evaluating UCART22 and UCART20x22. Cellectis holds a strong cash position of $721 million, expected to fund operations into 2026. Further updates are anticipated with presentations scheduled for upcoming conferences.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended
Cellectis S.A. has released its unaudited condensed consolidated financial statements for the three- and nine-month periods ending September 30, 2023. The report indicates a net loss of $58,197, worse than the previous year's loss, while total assets have decreased significantly. Revenues have fallen to $7,203, and operating expenses remain substantial at $74,926, suggesting continuing financial challenges. The report includes cautionary statements regarding forward-looking projections due to various risks prevalent in the biotech sector.
Read more →CLLS▲ +172.2%on this news· ran to +210% by day 1shared move
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
Cellectis, a clinical-stage biotechnology company, announced that it will report its financial results for the third quarter of 2023 on November 6, 2023. Following the release, the company will hold an investor conference call to discuss these results and provide updates on its business activities. Cellectis continues to focus on developing life-saving cell and gene therapies utilizing its gene-editing platform. The company's headquarters are located in Paris, France, with other locations in New York and Raleigh.
Read more →CLLS▲ +172.2%on this news· ran to +210% by day 1shared move
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca,
Cellectis has announced the signing of a Subsequent Investment Agreement with AstraZeneca for a $140M equity investment. This agreement was previously disclosed on November 1, 2023, and involves AstraZeneca subscribing to convertible preferred shares. The closing of the investment is contingent on shareholder approval and regulatory clearance, after which AstraZeneca is expected to own approximately 44% of Cellectis. Cellectis focuses on developing gene-editing therapies, primarily in oncology.
Read more →CLLS▲ +172.2%on this news· ran to +210% by day 1shared move
Confidential CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVAT
Cellectis S.A. and AstraZeneca Ireland Limited have formalized a joint research and collaboration agreement as of November 1, 2023. This partnership aims to develop licensed products, with AstraZeneca making an initial investment of $80 million in Cellectis. The agreement outlines various aspects of their collaboration, including research programs, licensing rights, and governance structure. Both companies are committed to leveraging their resources to advance cancer-targeting therapies.
Read more →CLLS▲ +172.2%on this news· ran to +210% by day 1shared move
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca Collaboration leverages Cellectis gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene ther
Cellectis has announced a significant strategic collaboration with AstraZeneca, involving an $80M initial equity investment and potential additional funding. The agreement focuses on the development of up to 10 novel cell and gene therapy candidates using Cellectis's gene editing technologies. AstraZeneca will support research costs and may gain substantial control over the collaboration's outcomes, with a significant share in Cellectis upon subsequent investments. This partnership will potentially enhance Cellectis's capabilities in delivering innovative therapeutics but also subjects it to AstraZeneca's oversight on key business decisions.
Read more →CLLSTranslation for information purposes only CELLECTIS French soci t anonyme (corporation) with share capital of 2,779,188.40 euros Registered office : 8 rue de la Croix Jarry, 75013 Paris Paris Trade and Companies Registry
Cellectis, a French corporation, has outlined various details regarding its share capital and operational purposes. The company has a registered share capital of approximately €2.78 million, divided into over 55 million shares. It engages in genome engineering and related activities across multiple sectors, including pharmaceuticals. The corporate governance structure involves a Board of Directors, with provisions for share transfers and shareholder rights detailed in its bylaws.
Read more →CLLSCellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Cellectis has announced the presentation of pre-clinical data on their MUC1-CAR T-cells at the upcoming SITC 2023 meeting. The study reveals that combining ΔPD1-IL12 with TGFBR2 knockout enhances CAR-T cell activity while limiting their accumulation outside tumors. This suggests a potential reduction in off-tumor toxicity, marking a significant advancement in targeting triple-negative breast cancer. The data reflect Cellectis's commitment to addressing challenges in solid tumor therapies using innovative gene-editing techniques.
Read more →CLLS▼ -12.5%on this news
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
Cellectis announced it will present significant pre-clinical data at the ESGCT 30th Annual Congress, focusing on gene therapy for HSPC and TALE-BE editing. The presentations include findings on TALEN-mediated gene editing that demonstrate efficient correction of sickle cell mutations and the potential for improved therapeutic outcomes. The company aims to highlight innovative approaches that could enhance the precision and effectiveness of gene therapy techniques. With over 23 years of expertise in gene editing, Cellectis continues to innovate in the biopharmaceutical landscape.
Read more →CLLSCellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Cellectis announced that it will present pre-clinical data on MUC1-CAR T-cells at the Society for Immunotherapy of Cancer's 38th Annual Meeting in San Diego from November 1-5, 2023. The presented data aims to address challenges in targeting solid tumors, particularly in triple-negative breast cancer. The poster will showcase the synergistic effects of TGF-Beta blockade and IL12 secretion activation in optimizing the potency of MUC1-CAR T-cells. Cellectis' work highlights their pioneering role in developing allogeneic CAR T-cell therapies through their gene-editing platform.
Read more →CLLS▼ -9%on this news
PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended
Cellectis S.A. has released its unaudited condensed consolidated financial statements for the six-month period ending June 30, 2023. The report outlines a net loss and a decline in overall assets, reflecting financial struggles for the company. Operating expenses have decreased compared to the previous year, but a significant loss remains evident. The document also includes various forward-looking statements subject to risks and uncertainties which may impact future operations.
Read more →CLLSCellectis Provides Full Report for Second Quarter 2023 Financial Results
Cellectis S.A. reported its second quarter 2023 financial results, revealing a net loss attributable to shareholders of $40.7 million. Despite a decrease in R&D expenses, a reduction in overall revenues was observed, down to $5.6 million from $6.5 million year-over-year. The company has $89 million in cash, projected to support operations into the third quarter of 2024. Additionally, financial gains from the deconsolidation of Calyxt were noted, yet overall financial performance continues to reflect challenges.
Read more →CLLSCellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Cellectis has provided updates on its clinical and preclinical programs alongside preliminary financial results for the second quarter of 2023. The company demonstrated positive data from its BALLI-01 trial evaluating UCART22 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Additionally, Cellectis continues to advance various CAR T-cell programs and preclinical research, with a strong cash position projected to sustain operations through the next year. Future data releases are anticipated later this year, highlighting ongoing advancements in their gene-editing technologies.
Read more →CLLSCellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
Cellectis S.A. will report its second quarter 2023 financial results on August 3, 2023, after the U.S. market closes. An investor conference call and webcast is scheduled for August 4, 2023, to discuss the results and provide updates on business activities. The company continues to focus on its pioneering gene-editing platform and allogeneic CAR-T immunotherapies in oncology. Cellectis aims to harness the immune system to treat various diseases with unmet medical needs.
Read more →CLLSCellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
Cellectis S.A. held its annual shareholders' general meeting on June 27, 2023, in Paris. Over 72% of shares participated in the voting process, resulting in the adoption of resolutions 1 through 28, while resolution 29 was rejected. The company remains focused on its pioneering gene-editing platform to advance cell and gene therapies for various diseases.
Read more →CLLS▲ +5.1%on this newsshared move
Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on
Cellectis S.A. held its annual general meeting on June 27, 2023, in Paris, where resolutions 1 through 28 were adopted while resolution 29 was rejected. The meeting saw more than 72% of shares exercised, reflecting significant participation from shareholders. The company, a clinical-stage biotechnology firm, is recognized for its innovative gene-editing platform aimed at developing therapies for various diseases. Cellectis focuses on CAR-T immunotherapies and has been active in the field for over 23 years.
Read more →CLLSCellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
Cellectis recently presented updated clinical and translational data on its BALLI-01 clinical trial, evaluating UCART22 for relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) at the EHA 2023. The results indicated promising preliminary safety and efficacy, with responses observed in patients who previously failed multiple lines of treatments. Although no dose-limiting toxicities were reported, some serious adverse events occurred, prompting a need for careful monitoring. Cellectis continues to advance its study with ongoing patient enrollment and plans for future data releases.
Read more →CLLSCellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
Cellectis showcased preclinical data at the ISCT 2023 event, highlighting their first allogeneic dual CAR T-cell product candidate, UCART20x22, aimed at treating B-cell malignancies. The data presented reflects strong in vitro and in vivo activities against tumors with varying antigen expression. Additionally, Cellectis reported advancements in TALEN® technology for gene correction of sickle cell mutation. The presentations aimed to emphasize the company's commitment to developing innovative cell and gene therapies addressing unmet medical needs in patients.
Read more →CLLSCellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
Cellectis published an article in Cancer Immunology Research presenting preclinical data on UCART20x22, its first allogeneic dual CAR T-cell product candidate. This therapy targets CD20 and CD22 antigens to address resistance seen in existing CAR T-cell therapies for B-cell Non-Hodgkin lymphoma. The study showed that UCART20x22 is capable of effectively eradicating tumor cells with heterogeneous antigen expression. Additionally, this product aims to offer an off-the-shelf solution for patients whose traditional therapies have failed.
Read more →CLLSCELLECTIS A corporation ( SA ) with a share capital of 2.779.188,40 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the Company ) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHO
Cellectis S.A. held its combined general meeting to address the year's financial results, revealing a substantial loss of €123.8 million for the fiscal year ending December 31, 2022. The meeting included discussions on the approval of annual financial statements and the allocation of these losses into retained earnings. The company has not distributed dividends for three consecutive years, reflecting ongoing financial challenges. Additionally, several board members were reappointed, indicating efforts to maintain leadership stability despite the financial situation.
Read more →CLLSCellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
Cellectis presented new clinical data on its AMELI-01 trial involving UCART123 for treating relapsed/refractory acute myeloid leukemia at ASGCT 2023. The trial showed promising results, with significant UCART123 expansion and preliminary evidence of anti-tumor activity in some patients. Additionally, Cellectis showcased advances in multiplex engineering to enhance CAR T-cell efficacy, indicating that these methods can lead to improved treatments for solid tumors.
Read more →CLLSCellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
Cellectis has published an article in Frontiers in Immunology detailing pre-clinical data on a new CAR T immunotherapy strategy targeting stroma-rich solid tumors. Utilizing its TALEN gene-editing technology, Cellectis engineered UCART T-cells to deplete cancer-associated fibroblasts, thus rendering tumors more susceptible to subsequent treatments. The results from mouse models indicated significant tumor growth reduction and enhanced antitumor effects. This novel approach could potentially revolutionize treatment options for challenging cancers like triple-negative breast cancer.
Read more →CLLS▼ -5.7%on this newsshared move
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
Cellectis announced the acceptance of an abstract for their BALLI-01 clinical trial presentation at the European Hematology Association 2023 Congress. The trial evaluates UCART22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, demonstrating good safety and preliminary efficacy results. The presentation, scheduled for June 8-15, will provide updated clinical and translational data aimed at addressing the needs of this heavily pretreated patient population.
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended
Cellectis S.A. released its unaudited condensed consolidated financial statements for the three-month period ending March 31, 2023. The report shows a net income loss of $32.5 million, reflecting a continued decline compared to the same period in the previous year. Forward-looking statements in the report highlight potential uncertainties that may affect future operations and financial performance. The company also noted significant operating expenses and challenges related to achieving profitability.
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for First Quarter 2023
Cellectis has provided a business update and reported its first-quarter financial results for 2023. The company announced the first successful dosing of a patient with its UCART22 candidate in Europe, marking a significant development in its clinical trials for B-cell acute lymphoblastic leukemia. In parallel, it shared promising preclinical data on its TALEN®-edited CAR T-cells. However, Cellectis has decided to halt enrollment in its MELANI-01 trial for UCARTCS1 to allocate resources more efficiently to its other ongoing studies.
Read more →CLLS▼ -6.4%on this newsshared move
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Cellectis has announced an oral presentation on its Phase 1 AMELI-01 clinical trial involving UCART123 at the upcoming ASGCT Annual Meeting. Preliminary data indicates that the addition of alemtuzumab to the lymphodepletion regimen led to enhanced UCART123 cell expansion and improved activity in patients with relapsed/refractory acute myeloid leukemia. Additionally, Cellectis will present findings on multiplex engineering techniques aimed at optimizing CAR T-cell therapies for treating solid tumors. These developments demonstrate Cellectis' commitment to advancing gene-editing technology in oncology.
Read more →CLLSCellectis to Report First Quarter 2023 Financial Results on May 4, 2023
Cellectis announced it will report its first-quarter 2023 financial results on May 4, 2023, followed by an investor conference call on May 5. The company is focused on advancing its gene-editing platform, which is instrumental in developing therapies aimed at treating various conditions, particularly in oncology. As a clinical-stage biotechnology firm with over 22 years of experience, Cellectis emphasizes its commitment to addressing unmet medical needs with its cutting-edge technologies, TALEN® and PulseAgile.
Read more →CLLSCellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
Cellectis has initiated the use of alemtuzumab, coded as CLLS52, in its lymphodepletion regimen for clinical trials involving different relapsed and refractory blood cancers. This move is part of the company's ongoing research to enhance the efficacy of its allogeneic CAR T-cell therapies. The addition of alemtuzumab is associated with better lymphodepletion, expanded cell activity, and significant clinical results in trials for UCART22, UCART123, and UCART20x22. Cellectis has an ongoing partnership with Sanofi, which supplies alemtuzumab for these studies.
Read more →CLLSCellectis Presents Preclinical Data on TALEN -edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
Cellectis presented preclinical data on TALEN-edited MUC1 CAR T-cells at the AACR Annual Meeting, demonstrating their efficacy in targeting triple negative breast cancer (TNBC). The data indicated that these allogeneic CAR T-cells could perform effectively in the immunosuppressive tumor microenvironment, which is a significant challenge for cancer therapies. MUC1, being overexpressed in TNBC patients, serves as a promising target for these therapies. The potential success of this treatment could address the unmet needs of patients with limited therapeutic options.
Read more →CLLSCellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
Cellectis announced the successful dosing of the first patient in Europe with its allogeneic CAR T-cell product candidate, UCART22, during the BALLI-01 study. This trial aims to evaluate the efficacy of UCART22 in treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) following lymphodepletion. By utilizing its proprietary manufacturing facilities in both France and North Carolina, Cellectis is well-positioned to streamline treatment plans and timelines. The UCART22 product candidate specifically targets the CD22 antigen, providing potentially new therapeutic options for patients who have not responded to previous therapies.
Read more →CLLSCellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of 20 million New York, NY
Cellectis has entered into a warrant agreement with the European Investment Bank (EIB), finalizing a credit facility agreement for up to $40 million. The company will draw down the first tranche of $20 million, which will be allocated to the advancement of its CAR T-cell product candidates. The agreement requires compliance with certain clinical development milestones, and the successful issuance of warrants to EIB as part of the disbursement conditions. The terms also include future financing possibilities should additional conditions be met.
Read more →CLLSCellectis Announces Poster Presentation on TALEN -edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Cellectis has announced the presentation of preclinical data on its CAR T-cells targeting triple negative breast cancer at the upcoming AACR Annual Meeting. The data will showcase innovative strategies aiming to enhance CAR T-cell efficacy while maintaining safety, particularly through specialized gene editing technology. This research targets the MUC1 antigen, which is overexpressed in many TNBC patients, addressing an urgent medical need in an area with limited treatment options. The presentation will occur on April 16, 2023, in Orlando, Florida.
Read more →CLLSCellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Cellectis provided a business update and announced its financial results for the fourth quarter and full year 2022. The company secured a credit facility of €40 million and closed a follow-on equity offering of $25 million to support its development efforts. Cellectis presented promising preliminary clinical data from its BALLI-01 and AMELI-01 studies involving UCART22 and UCART123, respectively, while also focusing on patient recruitment for several ongoing Phase 1 clinical trials. The first patient was dosed with the in-house manufactured UCART22 product candidate, enhancing the company's operational capabilities.
Read more →CLLSCellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
Cellectis, a clinical-stage biotechnology company, will report its fourth quarter and year-end 2022 financial results on March 8, 2023. The report will precede a conference call and live webcast on March 9, 2023, where the company will discuss its financial performance and business updates. Cellectis focuses on developing life-saving cell and gene therapies, utilizing its TALEN® gene-editing technology and innovative electroporation system.
Read more →CLLS▼ -5.5%on this news
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
Cellectis S.A. announced the successful initial closing of its global offering, which raised approximately $24.77 million. This includes the exercise of underwriters' options for additional shares, generating a total of 9,907,800 ADS issued. The funds will support the clinical development of multiple gene-editing therapies. Following this offering, Cellectis expects its financial resources to sufficiently fund operations into Q2 2024.
Read more →CLLS▼ -23%on this newsshared move
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
Cellectis S.A. has announced the pricing of its global offering, which involves the issuance of 8,800,000 American Depositary Shares (ADS) at a price of $2.50 per ADS. This capital increase is anticipated to be finalized around February 7, 2023, subject to customary conditions. Key shareholders are expected to receive over half of the ADSs sold, which could strengthen their ownership in the company. The ordinary shares on Euronext Growth in Paris were temporarily suspended but are set to resume trading soon.
Read more →CLLS▼ -23%on this newsshared move
Cellectis Announces Pricing of Follow-On Offering
Cellectis S.A. has announced the pricing of its follow-on global offering of 8,800,000 American Depositary Shares (ADS), priced at $2.50 each, expected to raise about $20.2 million. The company plans to utilize these proceeds primarily for the clinical development of various UCART therapies and other corporate purposes. The offering will lead to an approximate dilution of 16.2% in its existing share capital. The completion of the offering is anticipated around February 7, 2023, subject to customary closing conditions.
Read more →CLLS▲ +5.2%on this news· ran to -23% by day 3shared move
Cellectis Announces Launch of Follow-On Offering
Cellectis S.A. has announced a global offering of $22 million in American Depositary Shares (ADS) to support the ongoing clinical development of its gene-editing therapies. The offering, which will be underwritten by Jefferies LLC and Barclays Capital Inc., aims to facilitate the advancement of specific product candidates. However, the conclusion of the offering is contingent on market conditions and may be subject to adjustments. The company has a well-established reputation in the biotech field, focusing on innovative cancer treatments.
Read more →CLLSCellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Cellectis has amended the financial terms of a $20 million convertible note originally issued by Cytovia Therapeutics under a collaboration agreement. The revised note includes provisions for automatic conversion into Cytovia's common stock under specific conditions and an increase in the interest rate to 10% per annum. Furthermore, the repayment structure has been adjusted to require repayment of 50% of the outstanding amount by April 30, 2023, while extending the final maturity date to June 30, 2023. This collaboration focuses on developing innovative cell and gene therapies to address significant unmet medical needs in oncology.
Read more →CLLSCellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Cellectis S.A. has launched an At-The-Market (ATM) program to potentially raise up to $60 million in gross proceeds through the sale of American Depositary Shares on Nasdaq. The company plans to use the proceeds for the clinical development of its gene-editing therapies and general corporate purposes. The ATM program is designed to be effective until July 2025, potentially diluting current shares by approximately 23.04%. Eligible investors will be able to purchase shares under specific terms laid out in the sales agreement with Jefferies LLC.
Read more →CLLSCellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
The credit facility will enable Cellectis to support the development of its UCART product candidates pipeline The credit facility consists of three tranches of €20 million, €15 million, and €5 million respectively, each redeemable in fine in 6 years The credit facility is part
Read more →CLLSCellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complication NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering
Read more →CLLSThis presentation (together with the corresponding webcast, this "Presentation") contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform
Commitment to a Cure Cellectis Clinical Update December 2022 NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA Exhibit 99.1 This presentation (together with the corresponding webcast, this "Presentation") contains "forward-looking" statements within the meaning of applicable securities l
Read more →CLLSCellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that co
Read more →CLLSCellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the
Read more →CLLS▲ +12.6%on this news
Cellectis Presents Pre-Clinical Data on TALEN -edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data
Read more →CLLS▲ +12.6%on this news
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN and TALE Base Editors (TALE-BE)
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a manuscript in Fronti
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month period ended
The unaudited condensed Consolidated Financial Statements for the three and nine-month period ended September 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ( IAS 34 ) Interim Financial Reporting as issued by the Internation
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on UCARTCS1 selected for poster presentation, in collaboration with the Amsterdam University Medical Center Preclinical data on TALEN®-edited smart CAR T-cells to be presented at SI
Read more →CLLSCellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
• AMELI-01 (evaluating UCART123) abstract, selected for oral presentation, highlights that adding alemtuzumab was associated with improved activity • UCARTCS1 abstract, selected for poster presentation, demonstrated anti-tumor activity in vivo and in vitro supporting the potenti
Read more →CLLSCellectis to Report Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results f
Read more →CLLSCellectis Presents Data on Two TALEN -based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the Company will p
Read more →CLLSCellectis to Present Pre-Clinical Data on TALEN -edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data
Read more →CLLSCellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mar
Read more →CLLS▼ -6%on this news
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management plans
Read more →CLLS▲ +5.1%on this newsshared move
PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-months periods ended
P1YP1YP3Y0.00500.0050.010.020.10.0125 The unaudited condensed Consolidated Financial Statements for the three and six-months periods ended June 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")- Interim Financial Re
Read more →CLLS▼ -6%on this news
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin Lymphoma Cellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in May Mr. Axel-Sven Malkomes & Dr. Donald A Bergstrom,
Read more →CLLS▲ +14.5%on this newsshared move
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to begin in second half of the year N
Read more →CLLSCellectis to Report Second Quarter 2022 Financial Results
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results f
Read more →CLLSCellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes research data on its no
Read more →CLLS▼ -9.3%on this newsshared move
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual
Read more →CLLS▼ -9.3%on this newsshared move
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France. At the meeting, during which 67.23% of voting rights were exercised, Resolutions
Read more →CLLSCellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its combined general me
Read more →CLLSCellectis Annual Shareholders General Meeting to be Held on
Cellectis Annual Shareholders General Meeting to be Held May 23, 2022 New York (N.Y.) Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced to
Read more →CLLSCELLECTIS A corporation ( SA ) with a share capital of 2,274,215.50 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris (the Company ) NOTICE OF MEETING COMBINED GENERAL MEETING OF SHAREHO
( SA ) with a share capital of 2,274,215.50 euros Headquarters: 8, rue de la Croix Jarry - 75013 Paris 428 859 052 T.C.R. Paris COMBINED GENERAL MEETING OF SHAREHOLDERS shareholders are hereby informed that they are convened to the combined general meeting to be held on 28 Ju
Read more →CLLSCellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research da
Read more →CLLS▲ +5.2%on this news· ran to +20% by day 3shared move
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN ◦ Received a $20
Read more →CLLSCellectis to Report First Quarter 2022 Financial Results
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report fina
Read more →CLLSCellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cells Preclinical data shows proof-of-principle that UCART123 cells have potent anti-BPDCN activity Human evaluation of UCART123 is currently in Phase
Read more →CLLSCellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Cellectis is developing custom TALEN® for Cytovia to develop gene-edited iPSC-derived Natural Killer cells Cytovia and Isleworth Healthcare Acquisition Corp. announce business combination agreement and combined company is expected to be listed on NASDAQ under the ticker symbol I
Read more →CLLSCellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR T has been designed and engineered on the TRAC / CD52 TALEN® platform UCART20x22 expected to be Cellectis’ first product candidate fully designed, developed
Read more →CLLSCellectis to Participate in Two Upcoming Investor Conferences in March
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management will p
Read more →CLLS▼ -8.7%on this news
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results
Encouraging preliminary results from BALLI-01 study (evaluating UCART22) in relapsed/refractory B-cell Acute Lymphoblastic Leukemia presented at ASH 2021 annual meeting; BALLI-01 currently enrolling at DL3 On track for planned 2022 IND submission for UCART20x22, our first alloge
Read more →CLLSCellectis to Hold Fourth Quarter 2021 Earnings Call on Friday March 4, 2022 at 8:00AM EST
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that it will report its financial results for
Read more →CLLS▼ -11%on this newsshared move
BUSINESS Company Overview Calyxt, Inc. was founded in 2010 and incorporated in Delaware. Calyxt is a plant-based synthetic biology company that leverages its proprietary PlantSpring technology platform to engineer plant
founded in 2010 and incorporated in Delaware. Calyxt is a plant-based synthetic biology company that leverages its proprietary PlantSpring technology platform to engineer plant metabolism to produce innovative, high-value plant-based chemistries for use in customers materials an
Read more →CLLSCellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the appointment of Bing C. Wang, PhD, M
Read more →CLLSCellectis Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials o Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN Gene Editing o
Cellectis Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials January 10, 2022 New York (N.Y.) Cellectis (Euronext Growth: ALCLS Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platfor
Read more →CLLSCellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion
Read more →CLLS▼ -5.6%on this news
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported business objectives for its products pipeline
Read more →CLLSCellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in BALLI-01 Phase 1 Study The addition of Alemtuzumab to FC (FCA) Resulted in Prolonged Host-Lymphocy
Read more →CLLSCellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage gene-editing company employing its core technology to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen recept
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
• Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01 • Partnered programs at ASH 2021 – ALPHA2 and UNIVERSAL abstracts selected fo
Read more →CLLSCellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic d
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month periods ended
unaudited condensed Consolidated Financial Statements for the three and nine-month periods ended September 30, 2021, included herein, have been prepared in accordance with International Accounting Standard 34 ( IAS 34 ) Interim Financial Reporting as issued by the International
Read more →CLLSCellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for
Read more →CLLSCellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic d
Read more →CLLSCellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for
Read more →CLLSCalyxt Announces New Strategic Direction to Provide Sustainable, Plant-Based Synthetic Biology Solutions to Expanded Group of End Markets and Diversified Base of Customers -Proprietary PlantSpring TM technology platform
Calyxt Announces New Strategic Direction to Provide Sustainable, Plant-Based Synthetic Biology Solutions to Expanded Group of End Markets and Diversified Base of Customers -Proprietary PlantSpringTM technology platform expanded and achieves rapid development of plant-based biom
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month periods ended
The unaudited condensed Consolidated Financial Statements for the three and six-month periods ended June 30, 2021, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34" )- Interim Financial Reporting as issued by the International
Read more →CLLSCellectis Announces Participation in Five Investor Conferences
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients. • Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B-cell malignancies, UCARTMESO (targeting mesothelin), and TALGlobin01
Read more →CLLSCellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for
Read more →CLLSCellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin), UCARTMUC1 (targeting Mucin 1),
Read more →CLLSCellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France. At the meeting, during which more than 66% of voting rights were exercised, Resol
Read more →CLLSNon binding, unofficial English translation for information purposes only. Original in French. CELLECTIS A French limited liability company (soci t anonyme) with share capital of 2,273,065,50 Registered Office: 8, rue de
Non binding, unofficial English translation for information purposes only. Original in French. CELLECTIS A French limited liability company (soci t anonyme) with share capital of 2,273,065,50 Registered Office: 8, rue de la Croix Jarry 75013 Paris Paris Trade and Companies Regis
Read more →CLLSCellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the fie
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical develop
Read more →CLLSCELLECTIS A French limited liability company ( soci t anonyme ) with a share capital of 2.272,740.50 Registered Office: 8, rue de la Croix Jarry 75013 Paris Paris trade and companies register No. 428 859 052 (the Company
liability company (soci t anonyme) with a share capital of 2.272,740.50 Registered Office: 8, rue de la Croix Jarry 75013 Paris Paris trade and companies register No. 428 859 052 SHAREHOLDERS MEETING Shareholders are hereby informed that they are invited to attend the combin
Read more →CLLSCellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). In the context of the Covid-19 pandemic and in accordance with Ordinance no. 2020-321 of March 25, 2020, the provisions of which were extended until July 31, 2021 by Decree no. 2021-25
Read more →CLLSCellectis Completes Sale of $47 million through its ATM program
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells
Read more →CLLSCellectis Completes Sale of $47 million through its ATM Program New York, NY
Completes Sale of $47 million through its ATM Program New York, NY, April 9, 2021 Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company ), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based
Read more →CLLSCellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in ad
Read more →CLLSCellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results
Read more →CLLSCalyxt Announces Dr. Yves Ribeill Appointed As Executive Chair Replacing CEO Jim Blome Roseville, MN
Calyxt Announces Dr. Yves Ribeill Appointed As Executive Chair Replacing February 19, 2021 Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, today announced that the Board of Directors has appointed Yves Ribeill, Ph.D., to the new role of Executive Chair of the Boar
Read more →CLLSCellectis: Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 01/31/2021 43,029,305
Read more →CLLSCellectis Announces Withdrawal of Follow-On Offering
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed
Read more →CLLSCellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Marrow
Read more →CLLSCellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortma
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
Sponsored program at ASH 2020 – Oral presentation of initial data for BALLI-01 clinical trial evaluating UCART22 product candidate in adult patients with R/R B-cell Acute Lymphoblastic Leukemia (B-ALL) Partnered programs at ASH 2020 – UNIVERSAL abstract selected for oral present
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the nine-month period ended
unaudited condensed Consolidated Financial Statements for the nine-month period ended September 30, 2020, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB
Read more →CLLSCELLECTIS - GENERAL ASSEMBLY - 11/04/2020 VOTE RESULTS Ordinary Resolutions For Against Vote withhold Shares represented by the votes Percentage of the share capital represented by the votes Out of vote voting Null votin
CELLECTIS - GENERAL ASSEMBLY - 11/04/2020 Ordinary Resolutions For Against Vote withhold Shares represented by the votes Percentage of the share capital represented by the votes Out of vote voting Null voting Nb Resolution Result Votes % Votes
Read more →CLLSCellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results
Read more →CLLSTranslation for information purposes only CELLECTIS A French limited liability company ( soci t anonyme ) with share capital of 2,123,283.45 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and compa
Translation for information purposes only A French limited liability company (soci t anonyme) with share capital of 2,123,283.45 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and companies register N . 428 859 052 OF COMBINED SHAREHOLDERS MEETING Shar
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the six-month period ended
unaudited condensed Consolidated Financial Statements for the six-month period ended June 30, 2020, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The
Read more →CLLSCellectis to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferen
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients MELANI-01 trial in r/r MM patients on hold; Cellectis is actively working with the FDA to safely resume the clinic
Read more →CLLSCellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results
Read more →CLLSCellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that Steve Doares, Ph.D., joins Cell
Read more →CLLSCellectis Reports Clinical Hold Placed on MELANI-01 Study
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the MELANI-01 trial has been placed on clinic
Read more →CLLSCellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 29, 2020
NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Paris, France. At the meeting, during which more than 63% of voting rights were exercised, Reso
Read more →CLLSCellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies
NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the publication of a new research paper released today in
Read more →CLLSCellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Leopold Bertea, Ph
Read more →CLLSCellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellec
Read more →CLLSTranslation for information purposes only CELLECTIS A French limited liability company ( soci t anonyme ) with share capital of 2.123.283,45 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and compa
Translation for information purposes only liability company (soci t anonyme) with share capital of 2.123.283,45 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and companies register N . 428 859 052 COMBINED SHAREHOLDERS MEETING Shareholders are hereby
Read more →CLLSCellectis Provides Business Update and Reports Financial Results for First Quarter 2020
Proprietary allogeneic CAR T-cell programs on track in Phase 1 dose escalation trials; AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients Appointed Chief Medical Officer, Carrie Brownstein, M.D., who joins from Celgene Construction pro
Read more →CLLSCellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report the first quarter 202
Read more →CLLSCellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer
NEW YORK, April 13, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Carrie Brownstei
Read more →CLLSUS Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies NEW YORK--
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies NEW YORK--(BUSINESS WIRE)--March 10, 2020--Regulatory News: Cellect
Read more →CLLSCellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results Enrollment ongoing in Phase 1 dose-escalation trials AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results Enrollment ongoing in Phase 1 dose-escalation trials AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients Expanding collaboration with Servie
Read more →CLLSCellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited a
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALL
Read more →CLLSCellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST NEW YORK--(BUSINESS WIRE)--February 25, 2020--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceu
Read more →CLLSCellectis and Servier Expand Collaboration on UCART19 Products Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, inc
Cellectis and Servier Expand Collaboration on UCART19 Products Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A NEW YORK--(BUSINESS WIRE)--February 18, 2
Read more →CLLSFirst Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process & New IND
First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process & New IND Number First Patient Dosed at MD Anderson Cancer Center
Read more →CLLSIovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Iovance Biotherapeutics Will Use TALEN Technology from Cellectis to Develop Gene-Edited TIL SAN CARLOS,
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Iovance Biotherapeutics Will Use TALEN Technology from Cellectis to Develop Gene-Edited TIL SAN CARLOS, Calif. & NEW YORK--(BUSINESS WIRE)--January 12, 2020--Iova
Read more →CLLSCellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology NEW YOR
Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology NEW YORK--(BUSINESS WIRE)--January 6, 2020--Cellectis (Paris:ALC
Read more →CLLSst Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center NEW YORK--(BUSINESS WIRE)
1 st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center NEW YORK--(BUSINESS WIRE)--December 2, 2019--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (
Read more →CLLSCellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immuno
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System N
Read more →CLLSCellectis Publishes Creation of "Smart CAR T-Cells" for Potentially Safer, More Effective Treatments for Cancer in Nature Communications Cellectis Researchers Build CAR T-Cells Able to Sense and React to Their Environmen
Cellectis Publishes Creation of "Smart CAR T-Cells" for Potentially Safer, More Effective Treatments for Cancer in Nature Communications Cellectis Researchers Build CAR T-Cells Able to Sense and React to Their Environment by Secreting Therapeutic Proteins That Improve Their Abil
Read more →CLLSPRELIMINARY NOTE The unaudited Condensed Consolidated Financial Statements for the three-month and nine-month periods ended
Table of Contents unaudited Condensed Consolidated Financial Statements for the three-month and nine-month periods ended September 30, 2019, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the Internationa
Read more →CLLSCellectis Reports Financial Results for Third Quarter and First Nine Months 2019 First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient scre
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma Patient screening ongoing with UCART22 in BALLI-01 Phase 1 dose-escala
Read more →CLLSFirst Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma Cellectis' UCARTCS1 MELANI-01 Trial Commenced at MD Anderson Cancer Center NEW YORK--(BUSINESS WIRE)
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma Cellectis' UCARTCS1 MELANI-01 Trial Commenced at MD Anderson Cancer Center NEW YORK--(BUSINESS WIRE)--October 29, 2019--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:C
Read more →CLLSCellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates Agreement covers manufacturing of clinical supply for Cellectis' UCART pipeline Manufacturing to take plac
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates Agreement covers manufacturing of clinical supply for Cellectis' UCART pipeline Manufacturing to take place at Lonza's GMP site in Geleen, Netherlands BASEL, Switz
Read more →CLLSPRELIMINARY NOTE The unaudited Condensed Consolidated Financial Statements for the three-month and six-month periods ended
unaudited Condensed Consolidated Financial Statements for the three-month and six-month periods ended June 30, 2019, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Bo
Read more →CLLSCellectis Reports Financial Results for Second Quarter and First Six Months 2019 FDA approved IND for UCARTCS1 - first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house man
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 FDA approved IND for UCARTCS1 - first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house manufacturing facilities: IMPACT in Raleigh, NC and SMART in
Read more →CLLSCellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way SWIFF-CAR, a Next Generation CAR with an Embedded On/Off-Switch Increases Safety for Patients and Extends Manufacturing Possibilities NEW YORK--
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way SWIFF-CAR, a Next Generation CAR with an Embedded On/Off-Switch Increases Safety for Patients and Extends Manufacturing Possibilities NEW YORK--(BUSINESS WIRE)--July 8, 2019--Regulatory News: Cellectis
Read more →CLLSCellectis S.A. Reports Results from Combined Shareholders Meeting Held on
Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 New York Cellectis S.A. held its Combined Shareholders Meeting (Euronext Growth: ALCLS; Nasdaq: CLLS) on June 25, 2019 at its head office in Paris. At the meeting, during which more than 68
Read more →CLLSPRELIMINARY NOTE The unaudited Condensed Consolidated Financial Statements as of and for the three-month period ended
Table of Contents unaudited Condensed Consolidated Financial Statements as of and for the three-month period ended March 31, 2019, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounti
Read more →CLLSCellectis Reports Financial Results for First Quarter 2019 - Started construction of in-house manufacturing facilities IMPACT and SMART - FDA approved IND for UCARTCS1A product candidate in Multiple Myeloma - Published n
Reports Financial Results for First Quarter 2019 Started construction of in-house manufacturing facilities IMPACT and approved IND for UCARTCS1A product candidate in Multiple Myeloma Published novel manufacturing methods to improve allogeneic CAR T-cell of $425 million as of
Read more →CLLSNon binding, unofficial English translation for information purposes only. Original in French. CELLECTIS A French limited liability company ( soci t anonyme ) with share capital of 2,121,503.45 Registered Office: 8, rue
Non binding, unofficial English translation for information purposes only. liability company (soci t anonyme) with share capital of 2,121,503.45 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and companies register No. 428 859 052 COMBINED SHAREHOLDERS
Read more →CLLSCellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting - Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma - Poster presentation to
Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting presentation to include preclinical UCARTCS1A data in Multiple Myeloma Poster presentation to focus on improved manufacturing for allogeneic NEW YORK--(BUSINESS WIRE)--April 17, 2
Read more →CLLSFDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Successful manufacturing and release of GMP vials of UCARTCS1 NEW YORK--(BUSINESS WIRE)
Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients manufacturing and release of GMP vials of UCARTCS1 NEW YORK--(BUSINESS WIRE)--April 2, 2019--Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical com
Read more →CLLSCellectis Reports 4th Quarter and Full Year 2018 Financial Results UCART123 in Phase 1 dose escalation clinical trial ongoing for AML; UCART22 received FDA and IRB approvals for Phase 1 dose escalation clin
Cellectis Reports 4th Quarter and Full Year 2018 Financial Results New York, N.Y. March 11, 2019 at 4:10pm Eastern Time Cellectis S.A. (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited
Read more →CLLSCellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio NEW YORK--(BUSINESS WIRE)
Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio NEW YORK--(BUSINESS WIRE)--March 7, 2019--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical comp
Read more →CLLSCellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents m
Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediato
Read more →CLLSCellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing NEW YORK--(BUSINESS WIRE)
Appoints William Monteith as Senior Vice President U.S. Manufacturing NEW YORK--(BUSINESS WIRE)--December 10, 2018--Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T
Read more →CLLSCellectis Reports Financial Results for 3 rd Quarter and First Nine Months 2018 UCART123 in Phase 1 clinical trial for AML and BPDCN patients; UCART22 Phase 1 study protocol approved by FDA for B-ALL patients; UCART19 AS
Reports Financial Results for 3rd Quarter and First Nine Months 2018 in Phase 1 clinical trial for AML and BPDCN patients; Phase 1 study protocol approved by FDA for B-ALL patients; ASH abstract by partner Servier shows continued progress of first clinical allogeneic CAR T-c
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month and nine-month periods ended
unaudited condensed Consolidated Financial Statements for the three-month and nine-month periods ended September 30, 2018, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standa
Read more →CLLSCAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board NEW YORK--(BUSINESS WIRE)
Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board NEW YORK--(BUSINESS WIRE)--September 19, 2018--Regulatory News: Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR
Read more →CLLSCalyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP MINNEAPOLIS-ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP MINNEAPOLIS-ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--September 18, 2018--Regulatory News: Calyxt, Inc. (NASDAQ:CLXT) and Cellectis S.A. (NASDAQ:CLLS - EURONEXT GROWTH: ALCLS) announced today the appoi
Read more →CLLSCellectis: Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO Calyxt to host conference call on Wednesday
Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO host conference call on Wednesday, August 22, 2018 at 8:30 a.m. ET - MINNEAPOLIS-ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--August 22, 2018--Regulatory News: Calyxt, Inc. (NASDAQ:
Read more →CLLSCellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer NEW YORK--(BUSINESS WIRE)
Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer NEW YORK--(BUSINESS WIRE)--August 2, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biop
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month and six-month periods ended
unaudited condensed Consolidated Financial Statements for the three-month and six-month periods ended June 30, 2018, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Bo
Read more →CLLSCellectis Reports Financial Results for 2 nd Quarter and First Six Months 2018 FDA approves UCART123 protocol amendment to accelerate clinical development in AML patients FDA approves IND for UCART22 in B-ALL patients, w
Reports Financial Results for 2nd Quarter and First Six Months 2018 approves UCART123 protocol amendment to accelerate clinical development in AML patients approves IND for UCART22 in B-ALL patients, which is the 3rd allogeneic gene-edited CAR T-cell product candidate approv
Read more →CLLSTranslation for information purposes only CELLECTIS A French soci t anonyme (corporation) with share capital of 2.120.005 Registered office : 8 rue de la Croix Jarry, 75013 Paris Paris Trade and Companies Registry no. 42
Translation for information purposes only soci t anonyme (corporation) with share capital of 2.120.005 Registered office : 8 rue de la Croix Jarry, Paris Trade and Companies Registry no. 428 859 052 Copy certified as true to the original by the Chairman and Chief Executive Of
Read more →CLLSCellectis S.A. Reports Results from Annual General Meeting Held on
Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 June 27, 2018 (4:30pm CEST) New York (N.Y.) Cellectis S.A. Annual General Meeting (Euronext Growth: ALCLS Nasdaq: CLLS) was held on Tuesday, June 26, 2018 in Paris, at its head office. At the mee
Read more →CLLSCellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports CubiCAR, a Next Generation CAR, Allows for the Purification, Detection and Efficient Elimina
Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports a Next Generation CAR, Allows for the Purification, Detection and Efficient Elimination of CAR T-Cells NEW YORK--(BUSINESS WIRE)--June 12, 2018--Regulatory Ne
Read more →CLLSFDA Grants Cellectis IND Approval for UCART22 in B-ALL Cellectis' 3 rd TALEN -based Gene-Edited Allogeneic CAR T-Cell Product Candidate Entering Clinical Development NEW YORK--(BUSINESS WIRE)
Grants Cellectis IND Approval for UCART22 in B-ALL TALEN -based Gene-Edited Allogeneic CAR T-Cell Product Candidate Entering Clinical Development NEW YORK--(BUSINESS WIRE)--June 4, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq:
Read more →CLLSCellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Increase of current tested dose levels from 6.25x10 4 /kg to 2.5x10 5 /kg Treatment interval shortens between patients from 42 days to 2
of UCART123 Amendment in AML to Accelerate Clinical Development of current tested dose levels from 6.25x104/kg interval shortens between patients from 42 days to 28 days, then to 14 days for subsequent patients Anderson Cancer Center added as new clinical site for the AML stu
Read more →CLLSCellectis to Present Data at the 2018 ASGCT Annual Meeting NEW YORK--(BUSINESS WIRE)
to Present Data at the 2018 ASGCT Annual Meeting NEW YORK--(BUSINESS WIRE)--May 10, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Read more →CLLSCELLECTIS A French limited liability company ( soci t anonyme ) with share capital of 2,080,273.10 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and companies register No. 428 859 052 (the Company
liability company (soci t anonyme) with share capital of 2,080,273.10 Registered Office: 8, rue de la Croix Paris trade and companies register No. 428 859 052 COMBINED SHAREHOLDERS MEETING hereby informed that they are called to attend the combined shareholder s meeting to be
Read more →CLLSPRELIMINARY NOTE These unaudited condensed Interim Consolidated Financial Statements for the three-month period ended
These unaudited condensed Interim Consolidated Financial Statements for the three-month period ended March 31, 2018, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Bo
Read more →CLLSCellectis Reports 1 st Quarter 2018 Financial Results IND filed for UCART22 clinical investigation in ALL patients Allogene takes over Pfizer's rights under the Research and License Agreement with Cellectis, to accelerat
Quarter 2018 Financial Results filed for UCART22 clinical investigation in ALL patients takes over Pfizer's rights under the Research and License Agreement with Cellectis, to accelerate development and commercialization of allogeneic off-the-shelf UCART therapies Wyss Instit
Read more →CLLSCellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) This is the 3 rd IND filing for a TALEN -based Gene Edited Allogeneic UCART Product Candidate NEW YORK--(BUSINESS WIRE)
Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) IND filing for a TALEN -based Gene Edited Allogeneic UCART Product NEW YORK--(BUSINESS WIRE)--May 2, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-
Read more →CLLSHarvard's Wyss Institute Partners with Cellectis to Recode the Human Genome Recode project will use Cellectis' TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and
Wyss Institute Partners with Cellectis to Recode the Human Genome project will use Cellectis' TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies BOSTON & NEW YORK--(BUSINESS WIRE)--M
Read more →CLLSCellectis to Present Data at the 2018 AACR Annual Meeting NEW YORK--(BUSINESS WIRE)
Present Data at the 2018 AACR Annual Meeting NEW YORK--(BUSINESS WIRE)--April 11, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on ge
Read more →CLLSCellectis Announces Closing of Follow-On Offering NEW YORK--(BUSINESS WIRE)
Announces Closing of Follow-On Offering NEW YORK--(BUSINESS WIRE)--April 10, 2018--Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on ge
Read more →CLLSCellectis Announces Pricing of Follow-On Offering NEW YORK--(BUSINESS WIRE)
Announces Pricing of Follow-On Offering NEW YORK--(BUSINESS WIRE)--April 4, 2018--Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gen
Read more →CLLSCellectis Announces Launch of Follow-On Offering NEW YORK--(BUSINESS WIRE)
Announces Launch of Follow-On Offering NEW YORK--(BUSINESS WIRE)--April 3, 2018--Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS - EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene
Read more →CLLSCellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies Allogene intends to assume f
and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies intends to assume from Pfizer the global strategic collaboration agreement originally formed w
Read more →CLLSDr. Mathieu Simon to Retire as Cellectis' Chief Operating Officer; Elsy Boglioli Named as Successor NEW YORK--(BUSINESS WIRE)
Mathieu Simon to Retire as Cellectis' Chief Operating Officer; Elsy Boglioli Named as Successor NEW YORK--(BUSINESS WIRE)--March 13, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical compan
Read more →CLLSCellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44 th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting NEW YORK--(BUSINESS WIRE)
Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th Society for Blood and Marrow Transplantation) Annual NEW YORK--(BUSINESS WIRE)--March 8, 2018--Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASD
Read more →CLLSCellectis Reports 4 th Quarter and Full Year 2017 Financial Results First dose cohort of PhI intermediary data of UCART19 presented at ASH in December 2017, showing 83% CR rate in 12 high tumor burden ALL patients at D28
Quarter and Full Year 2017 Financial Results dose cohort of PhI intermediary data of UCART19 presented at ASH in December 2017, showing 83% CR rate in 12 high tumor burden ALL manufacturing of UCART22, representing already the third allogeneic, off-the-shelf, TALEN gene-edite
Read more →CLLSTwo Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells NEW YORK--(BUSINESS WIRE)
Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells NEW YORK--(BUSINESS WIRE)--February 13, 2018--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allog
Read more →CLLSTranslation for information purposes only CELLECTIS A French soci t anonyme (corporation) with share capital of 1,797,973.10 Registered office: 8 rue de la Croix Jarry, 75013 Paris Paris Trade and Companies Registry no.
Translation for information purposes only soci t anonyme (corporation) with share capital of 1,797,973.10 Registered office: 8 rue de la Croix Jarry, Paris Trade and Companies Registry no. 428 859 052 Translation for information purposes only The Company is a corporation (so
Read more →CLLSPreliminary Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials NEW YORK--(BUSINESS WIRE)
Data from Servier and Pfizer's UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials NEW YORK--(BUSINESS WIRE)--December 12, 2017--Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis
Read more →CLLSCellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development New Addition to Senior Leadership Team Brings to Cellectis In-Depth Corporate Strategy Expertise within the Pharmaceutical
Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development Addition to Senior Leadership Team Brings to Cellectis In-Depth Corporate Strategy Expertise within the Pharmaceutical and MedTech NEW YORK--(BUSINESS WIRE)--December 4, 2017--Regulatory Ne
Read more →CLLSCellectis Appoints Immuno-Oncology Leader St phane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer NEW YORK--(BUSINESS WIRE)
Appoints Immuno-Oncology Leader St phane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer NEW YORK--(BUSINESS WIRE)--December 4, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinic
Read more →CLLSCellectis Demonstrates Fine and Predictable Tuning of TALEN Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy Optimized multiplex gene editing for "off-the-shelf" PD-1 inhibition resistant CAR T-cells NEW Y
Demonstrates Fine and Predictable Tuning of TALEN Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy multiplex gene editing for "off-the-shelf" PD-1 inhibition resistant CAR NEW YORK--(BUSINESS WIRE)--November 20, 2017--Regulatory News: Cellectis (Paris:ALCLS) (N
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Interim Consolidated Financial Statements for the three-month and the nine-month periods ended
unaudited condensed Interim Consolidated Financial Statements for the three-month and the nine-month periods ended September 30, 2017, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accou
Read more →CLLSCellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 FDA has lifted the clinical hold from both Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and in blastic plasmacytoid dendri
Reports Financial Results for Third Quarter and First Nine Months of 2017 lifted the clinical hold from both Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell results of the first-in-human clinical trials of UCART19 will be
Read more →CLLSFDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN NEW YORK--(BUSINESS WIRE)
Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML NEW YORK--(BUSINESS WIRE)--November 6, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immun
Read more →CLLSCellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)
Announces Two Oral Presentations and One Poster Presentation at the 2017 NEW YORK--(BUSINESS WIRE)--November 1, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing imm
Read more →CLLSServier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59 th American Society of Hematology (ASH) Annual Meeting NEW YORK--(BUSINESS WIRE)
and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting NEW YORK--(BUSINESS WIRE)--November 1, 2017--Regulatory News: Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Par
Read more →CLLSMathieu Simon, M.D. Cellectis' EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer NEW YORK--(BUSINESS WIRE)
Simon, M.D. Cellectis' EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer NEW YORK--(BUSINESS WIRE)--October 4, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company foc
Read more →CLLSCellectis Reports Clinical Hold of UCART123 Studies NEW YORK--(BUSINESS WIRE)
Cellectis Reports Clinical Hold of UCART123 Studies NEW YORK--(BUSINESS WIRE)--September 4, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells
Read more →CLLSSEGMENT FINANCIAL INFORMATION SUPPLEMENT TO CELLECTIS S.A. S INTERIM REPORT FOR THE QUARTER AND SIX-MONTH PERIOD ENDED JUNE 30, 2017. PRELIMINARY NOTE On
SEGMENT FINANCIAL INFORMATION SUPPLEMENT TO CELLECTIS S.A. S INTERIM REPORT FOR THE QUARTER AND SIX-MONTH PERIOD ENDED JUNE 30, 2017. 2017, Cellectis filed its interim report for the quarter and six-month period ended June 30, 2017 (the Interim Report ) on Form 6-K. This suppl
Read more →CLLSCellectis' UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center UCART123 is First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YORK--(BUSINESS WIRE)
UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center is First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YORK--(BUSINESS WIRE)--August 17, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext:
Read more →CLLSPRELIMINARY NOTE The unaudited condensed Interim Consolidated Financial Statements for the three-month and the six-month periods ended
unaudited condensed Interim Consolidated Financial Statements for the three-month and the six-month periods ended June 30, 2017, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting
Read more →CLLSCalyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--July 25, 2017--Cellectis S.A. (NASDAQ:CLLS) and Calyxt, Inc. (NASDAQ:CLXT) announced today the closing of Calyxt's initial public offering
Read more →CLLSCellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--July 25, 2017--Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) and Calyxt, Inc. (NASDAQ:CLXT) announced today the
Read more →CLLSCellectis Reports Financial Results for 2 nd Quarter and First Six Months 2017 First AML patient treated with UCART123, our allogeneic CAR T product candidate in the Phase I dose-escalation study arm; enrollment ongoing
Reports Financial Results for 2nd Quarter and First Six Months 2017 AML patient treated with UCART123, our allogeneic CAR T product candidate in the Phase I dose-escalation study arm; enrollment ongoing clearance granted by the FDA to Servier and Pfizer related to the Phase
Read more →CLLSCellectis Granted Patent for CRISPR Use in T-Cells NEW YORK--(BUSINESS WIRE)
Granted Patent for CRISPR Use in T-Cells NEW YORK--(BUSINESS WIRE)--July 24, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CA
Read more →CLLSCellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--July 19, 2017--Regulatory Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) and Calyxt, Inc. announced today the pricing of Calyxt's initial public offering of 7,000,0
Read more →CLLSCellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
Calyxt Announces Proposed Initial Public Offering of $100.0 Million ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--July 10, 2017--Regulatory Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) and Calyxt, Inc. announced today that Calyxt has commenced a proposed initial public offering o
Read more →CLLSCellectis Appoints Rainer Boehm, M.D. and Herv Hoppenot to Board of Directors NEW YORK--(BUSINESS WIRE)
Appoints Rainer Boehm, M.D. and Herv Hoppenot to Board of Directors NEW YORK--(BUSINESS WIRE)--June 28, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherap
Read more →CLLSFirst in Human Administration of UCART123 in Cellectis' AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital UCART123 is the First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YOR
Human Administration of UCART123 in Cellectis' AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital is the First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YORK--(BUSINESS WIRE)--June 27, 2017--Regulatory News: Cellectis (Alternext:
Read more →CLLSExplanatory Note : The board of directors recommended a vote in favor of all resolutions with the exception of the Twenty-Ninth Resolution. TEXT OF RESOLUTIONS RESOLUTIONS WITHIN THE COMPETENCE OF THE ORDINARY SHAREHOLDE
Explanatory Note: The board of directors recommended a vote in favor of all resolutions with the exception of the Twenty-Ninth Resolution. RESOLUTIONS WITHIN THE COMPETENCE OF THE ORDINARY SHAREHOLDERS MEETING Approval of the financial statements for the financial year ended D
Read more →CLLSCalyxt Files Registration Statement for Proposed Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)
Files Registration Statement for Proposed Initial Public Offering ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--June 23, 2017--Regulatory Cellectis S.A. (Alternext : ALCLS ; Nasdaq : CLLS) and Calyxt, Inc. announced that Calyxt has publicly filed a registration statement on Fo
Read more →CLLSCellectis: Annual General Meeting of
Annual General Meeting of June 26, 2017 NEW YORK--(BUSINESS WIRE)--June 9, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR
Read more →CLLSCalyxt Names Joseph B. Saluri as General Counsel & EVP, Corporate Development ST. PAUL, Minn.--(BUSINESS WIRE)
Names Joseph B. Saluri as General Counsel & EVP, Corporate Development ST. PAUL, Minn.--(BUSINESS WIRE)--June 7, 2017--Regulatory News: Calyxt, Inc. (Paris:ALCLS) (NASDAQ:CLLS), a Minnesota-based company developing healthier specialty food ingredients to benefit both consumer
Read more →CLLSCalyxt Launches U.S. Field Trials with University of Minnesota for Powdery Mildew-Resistant Spring Wheat Variety Wheat Marks Calyxt's Fourth Gene Edited Crop to Undergo Trials MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIR
Launches U.S. Field Trials with University of Minnesota for Powdery Mildew-Resistant Spring Wheat Variety Marks Calyxt's Fourth Gene Edited Crop to Undergo Trials MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--May 16, 2017--Calyxt, Inc., a Minnesota-based company developing
Read more →CLLSCellectis Patent Encompassing Broad Uses of Gene Editing Technologies Maintained by USPTO U.S. Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as Zinc Finger Nucleases, TAL-effector Nucleases, Mega-TAL
Patent Encompassing Broad Uses of Gene Editing Technologies Maintained Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as Zinc Finger Nucleases, TAL-effector Nucleases, Mega-TALs and CRISPR-Cas9 to Perform Gene Insertion into Cell Genomes NEW YORK--(BUSINES
Read more →CLLSCalyxt Patent Encompassing Broad Uses of Plant Gene Editing Technologies Maintained by USPTO U.S. Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as Zinc Finger Nucleases, TAL-effector Nucleases, Mega-
Patent Encompassing Broad Uses of Plant Gene Editing Technologies Patent 8,921,332 Refers to the Use of Chimeric Endonucleases, such as Zinc Finger Nucleases, TAL-effector Nucleases, Mega-TALs and CRISPR/Cas9 to Precisely Edit DNA within Plant Genomes MINNEAPOLIS & ST. PAUL,
Read more →CLLSPRELIMINARY NOTE The unaudited first quarter consolidated Financial Statements included herein have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Acc
unaudited first quarter consolidated Financial Statements included herein have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The consolidated financial statements are pres
Read more →CLLSCellectis Reports 1 st Quarter 2017 Financial Results - Clinical trial approval by the FDA for wholly-owned UCART123 in AML & BPDCN patients at Weill Cornell and MD Anderson - IND clearance granted by the FDA to Servier
Quarter 2017 Financial Results Clinical trial approval by the FDA for wholly-owned UCART123 in AML & BPDCN patients at Weill Cornell and MD Anderson clearance granted by the FDA to Servier and Pfizer related to the Phase I clinical trials of UCART19 in ALL patients Consideri
Read more →CLLSCellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference Dr. Andr Choulika to Serve as Panelist for "Humankind vs. Cancer: The Scorecard" NEW YORK--(BUSINESS WIRE)
CEO Selected as Speaker for 2017 Milken Institute Global Conference Andr Choulika to Serve as Panelist for "Humankind vs. Cancer: The NEW YORK--(BUSINESS WIRE)--April 27, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharm
Read more →CLLSCORRECTING and REPLACING: Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)
and REPLACING: Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)--April 25, 2017--Regulatory News: This replaces the announcement made at 22:30 CET April 25, 2017 due to the following corrections: Under "Oral presenta
Read more →CLLSCellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)
to Present at the American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)--April 25, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based
Read more →CLLSCellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc. NEW YORK--(BUSINESS WIRE)
S.A. to Explore Possible Initial Public Offering of Calyxt, Inc. NEW YORK--(BUSINESS WIRE)--April 12, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offeri
Read more →CLLSCellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research NEW YORK--(BUSINESS WIRE)
to Present at the 2017 Annual Conference of the American Association for NEW YORK--(BUSINESS WIRE)--March 29, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based
Read more →CLLSCalyxt Hires Cargill Executive Manoj Sahoo as Chief Commercial Officer ST. PAUL, Minn.--(BUSINESS WIRE)
Hires Cargill Executive Manoj Sahoo as Chief Commercial Officer ST. PAUL, Minn.--(BUSINESS WIRE)--March 21, 2017--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, announced today that former Cargill executive Ma
Read more →CLLSCalyxt Announces New Technology Framework Agreement with Plant Bioscience Limited to Expand IP Portfolio ST. PAUL, Minn.--(BUSINESS WIRE)
Announces New Technology Framework Agreement with Plant Bioscience Limited to Expand IP Portfolio ST. PAUL, Minn.--(BUSINESS WIRE)--March 9, 2017--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, announced today
Read more →CLLSServier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia NEW YORK--(BUSINESS WIRE)
and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia NEW YORK--(BUSINESS WIRE)--March 9, 2017--Regulatory News: Servier, together with Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alter
Read more →CLLSFive Additional Leading Physicians to Join Cellectis Clinical Advisory Board New Board Members Include Hematology Experts Catherine Bollard, Herv Dombret, Ola Landgren, Marcela Maus & Dietger Niederweiser NEW YORK--(BUSI
Additional Leading Physicians to Join Cellectis Clinical Advisory Board Members Include Hematology Experts Catherine Bollard, Herv Dombret, Ola Landgren, Marcela Maus & Dietger Niederweiser NEW YORK--(BUSINESS WIRE)--March 7, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NA
Read more →CLLSCellectis Reports 4 th Quarter and Full Year 2016 Financial Results FDA approval to conduct Phase I clinical trials for UCART123 in AML & BPDCN patients UCART19 1 Phase I clinical trials ongoing in ALL patients; partial
Quarter and Full Year 2016 Financial Results approval to conduct Phase I clinical trials for UCART123 in AML & Phase I clinical trials ongoing in ALL patients; partial data presented at the NIH's RAC's meeting in December 2016 of Cellectis' Clinical Advisory Board cash posit
Read more →CLLSCellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday
to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30 p.m. ET in New York NEW YORK--(BUSINESS WIRE)--February 7, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopha
Read more →CLLSFDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. Cellectis' UCART123 Product Candidate Targets
Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S. UCART123 Product Candidate Targets AML and BPDCN NEW YORK--(BUSINESS WIRE)--February 6, 2017--Regulatory
Read more →CLLSCellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board New Board Members Include Professors John Gribben, Koen van Besien, Kanti Rai and Catherine Thieblemont NEW YORK--(BUSINESS WIRE)
Prominent Physicians to Join Cellectis Clinical Advisory Board Members Include Professors John Gribben, Koen van Besien, Kanti Rai and Catherine Thieblemont NEW YORK--(BUSINESS WIRE)--January 23, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS;
Read more →CLLSCellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions Publication in Scientific Reports , a Nature Publishing Group Journal NEW YORK--(BUSINESS WIRE)
Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions a Nature Publishing Group Journal NEW YORK--(BUSINESS WIRE)--January 22, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS), a biopharmaceutical company focused on developing immunotherapies bas
Read more →CLLSCellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday
to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT NEW YORK--(BUSINESS WIRE)--January 3, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on
Read more →CLLSCellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN NEW YORK--(BUSINESS WIRE)
Submits IND Application for UCART123, Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN NEW YORK--(BUSINESS WIRE)--January 3, 2017--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused
Read more →CLLSCellectis Announces Recombinant DNA Advisory Committee's (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN NEW YORK--(BUSINESS WIRE)
Announces Recombinant DNA Advisory Committee's (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN NEW YORK--(BUSINESS WIRE)--December 15, 2016--Regulatory News: Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on devel
Read more →CLLSCalyxt Appoints Seed & Trait Veteran Bryan Corkal to New Chief Financial Officer Role Expansion of Senior Leadership Team Further Solidifies Calyxt's Mission to Bring Foods with Healthier Characteristics to Market Faster
Appoints Seed & Trait Veteran Bryan Corkal to New Chief Financial of Senior Leadership Team Further Solidifies Calyxt's Mission to Bring Foods with Healthier Characteristics to Market Faster & More Efficiently ST. PAUL, Minn.--(BUSINESS WIRE)--December 5, 2016--Calyxt, Inc., a
Read more →CLLSPRELIMINARY NOTE These unaudited condensed Interim Consolidated Financial Statements for the three-month and nine-month periods ended
These unaudited condensed Interim Consolidated Financial Statements for the three-month and nine-month periods ended September 30, 2016 have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards
Read more →CLLSCellectis Reports Financial Results for 3 rd Quarter and First Nine Months 2016 - UCART19 Phase 1 trial on-going - Successful cGMP Manufacturing for UCART123 - Strong cash position of $295 million 1 as of
Reports Financial Results for 3rd Quarter and First Nine Months 2016 Phase 1 trial on-going Successful cGMP Manufacturing for UCART123 cash position of $295 million1 as of September 30, 2016 Additional grant of patent with broad claims covering fundamental use of gene edit
Read more →CLLSCellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY NEW YORK--(BUSINESS WIRE)
to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY NEW YORK--(BUSINESS WIRE)--November 21, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company
Read more →CLLSCalyxt Produces 1,200 Tons of High-Oleic Soybeans in U.S. MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)
Produces 1,200 Tons of High-Oleic Soybeans in U.S. MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--November 15, 2016--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, today announced that the Company has complet
Read more →CLLSCellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 NEW YORK--(BUSINESS WIRE)
Announces Successful cGMP Manufacturing for Second Product Candidate: NEW YORK--(BUSINESS WIRE)--November 15, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based
Read more →CLLSCellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)
Announces Two Oral Presentations and One Poster at the 2016 ASH Annual NEW YORK--(BUSINESS WIRE)--November 7, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based
Read more →CLLSCellectis Hosts World's First Gene Edited Dinner in NYC NEW YORK--(BUSINESS WIRE)
Hosts World's First Gene Edited Dinner in NYC NEW YORK--(BUSINESS WIRE)--October 31, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cel
Read more →CLLSCalyxt Generating Healthier High-Oleic Low-Linolenic Soybean Variety with Increased Oxidative Stability and Enhanced Shelf Life Article Available in BMC Plant Biology MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)
Generating Healthier High-Oleic Low-Linolenic Soybean Variety with Increased Oxidative Stability and Enhanced Shelf Life Available in BMC Plant Biology MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--October 31, 2016--Calyxt, Inc., a Minnesota-based company developing healthi
Read more →CLLSCalyxt Expands its Patent Portfolio, Now Encompassing Broad Uses of Technologies such as CRISPR/Cas9, Zinc Finger Nucleases and TAL-effector Nucleases for Plant Gene Editing U.S. Patents 9,458,439 and 8,921,332 are Now I
Expands its Patent Portfolio, Now Encompassing Broad Uses of Technologies such as CRISPR/Cas9, Zinc Finger Nucleases and TAL-effector Nucleases for Plant Gene Editing Patents 9,458,439 and 8,921,332 are Now Issued MINNEAPOLIS-ST. PAUL, Minn.--(BUSINESS WIRE)--October 4, 2016-
Read more →CLLSCellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 Two Patents of a Family Claiming the Basic Uses of Chimeric Restriction Nucleases for Gene Editing in Any
Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 Patents of a Family Claiming the Basic Uses of Chimeric Restriction Nucleases for Gene Editing in Any Type of Cells NEW YORK--(BUSINESS WIRE)--October 4, 2016--Regulatory N
Read more →CLLSCellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare NEW YORK--(BUSINESS WIRE)
Wins 2016 Most Innovative European Biotech SME Award for Healthcare NEW YORK--(BUSINESS WIRE)--September 27, 2016--Cellectis (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today an
Read more →CLLSCellectis Reports 2 nd Quarter and First Half Year 2016 Financial Results - First patient dosed in phase 1 clinical trial for UCART19 - UCART 123 manufacturing ongoing - Strong cash position of $300 million 1 ( 270 milli
Quarter and First Half Year 2016 Financial Results patient dosed in phase 1 clinical trial for UCART19 123 manufacturing ongoing cash position of $300 million1 ( 270 million) as of June 30, 2016 Revenues and other income of $20 million2 ( 18 million) in the 2nd quarter of 2
Read more →CLLSPRELIMINARY NOTE These unaudited condensed Consolidated Financial Statements for the three-month and the six-month periods ended
Table of Contents These unaudited condensed Consolidated Financial Statements for the three-month and the six-month periods ended June 30, 2016 have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting S
Read more →CLLSCellectis Named 2016 Technology Pioneer by the World Economic Forum NEW YORK--(BUSINESS WIRE)
Named 2016 Technology Pioneer by the World Economic Forum NEW YORK--(BUSINESS WIRE)--June 27, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited
Read more →CLLSMIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year NEW YORK--(BUSINESS WIRE)
Names Cellectis on Annual List of 50 Smartest Companies for Second NEW YORK--(BUSINESS WIRE)--June 27, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on ge
Read more →CLLSCellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) NEW YORK--(BUSINESS WIRE)
Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) NEW YORK--(BUSINESS WIRE)--June 20, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focu
Read more →CLLSCalyxt Appoints Federico A. Tripodi to New Role of CEO ST. PAUL, Minn.--(BUSINESS WIRE)
Appoints Federico A. Tripodi to New Role of CEO ST. PAUL, Minn.--(BUSINESS WIRE)--May 23, 2016--Calyxt, Inc., a Minnesota-based company developing healthier food products to benefit both consumers and growers, announced today the appointment of former Monsanto Corporation exe
Read more →CLLSCellectis Reports First Quarter 2016 Financial Results - Initiated UCART123 GMP production concept - Secured strategic supply of key materials for GMP manufacturing - Strong cash position of $315 million ( 276 million) a
Reports First Quarter 2016 Financial Results Initiated UCART123 GMP production concept strategic supply of key materials for GMP manufacturing cash position of $315 million ( 276 million) as of March, 31 2016 NEW YORK--(BUSINESS WIRE)--May 11, 2016--Regulatory News: Cellecti
Read more →CLLSCellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19 th American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)
to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)--May 2, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical compa
Read more →CLLSCELLECTIS A French limited liability company ( soci t anonyme ) with share capital of 1,758,930.70 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris trade and companies register No. 428 859 052 (the Company
liability company (soci t anonyme) with share capital of 1,758,930.70 Registered Office: 8, rue de la Croix Paris trade and companies register No. 428 859 052 COMBINED SHAREHOLDERS MEETING Shareholders are hereby informed that they are called to attend the combined sharehold
Read more →CLLSCellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies NEW YORK & PULLY, Switzerland--(BUSINESS WIRE)
and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies NEW YORK & PULLY, Switzerland--(BUSINESS WIRE)--March 16, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical
Read more →CLLSCellectis Reports Fourth Quarter and Full Year 2015 Financial Results - On track with submission of UCART19 Clinical Trial Application; Application Filed with MHRA (UK) - Encouraging data from the First-in-Human compassi
Reports Fourth Quarter and Full Year 2015 Financial Results track with submission of UCART19 Clinical Trial Application; Application Filed with MHRA (UK) Encouraging data from the First-in-Human compassionate use of UCART19 opt-in by Servier into UCART19; amendment with impro
Read more →CLLSCellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 NEW YORK--(BUSINESS WIRE)
Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 NEW YORK--(BUSINESS WIRE)--March 7, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focuse
Read more →CLLSCellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility NEW YORK--(BUSINESS WIRE)
Subsidiary Calyxt, Acquires Land for New Headquarters Facility NEW YORK--(BUSINESS WIRE)--March 1, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene e
Read more →CLLSCellectis Enters into New Agreement with CELL for CURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies NEW YORK & LES ULIS, France--(BUSINESS WIRE)
Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies NEW YORK & LES ULIS, France--(BUSINESS WIRE)--January 19, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopha
Read more →CLLSCellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions Publication in Scientific Reports , a Nature Publishing Group Journal NEW YORK--(BUSINESS WIRE)
Announces a New CAR Architecture Controlling CAR T-Cell Functions a Nature Publishing Group Journal NEW YORK--(BUSINESS WIRE)--January 11, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) today announced the publication of a study
Read more →CLLSCellectis Announces Chief Medical Officer Appointment to Senior Leadership Team NEW YORK--(BUSINESS WIRE)
Announces Chief Medical Officer Appointment to Senior Leadership Team NEW YORK--(BUSINESS WIRE)--January 7, 2016--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based
Read more →CLLSCellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies NEW YORK--(BUSINESS WIRE)
Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies NEW YORK--(BUSINESS WIRE)--December 23, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) today announc
Read more →CLLSCellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 NEW YORK--(BUSINESS WIRE)
Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 NEW YORK--(BUSINESS WIRE)--December 21, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical comp
Read more →CLLSCalyxt Announces Research Collaboration and Licensing Agreement for Trait Development in Wheat, Rice and Corn NEW BRIGHTON, Minn.--(BUSINESS WIRE)
Announces Research Collaboration and Licensing Agreement for Trait Development in Wheat, Rice and Corn NEW BRIGHTON, Minn.--(BUSINESS WIRE)--December 16, 2015--Calyxt, Inc., a Minnesota-based company focused on developing healthier food products to benefit both consumers and
Read more →CLLSServier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global License and Collaboration Agree
Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy Hematological Malignancies Also Enters Into Exclusive Global License and Collaboration Agreement with Pfizer to Co-Develop and Commercialize Therapy NEW YORK & SURESNE
Read more →CLLSCellectis Reports Third Quarter and First Nine Months 2015 Financial Results NEW YORK--(BUSINESS WIRE)
Reports Third Quarter and First Nine Months 2015 Financial Results NEW YORK--(BUSINESS WIRE)--November 16, 2015--Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UC
Read more →CLLSCellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)
First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting NEW YORK--(BUSINESS WIRE)--November 5, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) today announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will presen
Read more →CLLSCalyxt Completes Second Year of Field Trials of its High Oleic Soybean Product NEW BRIGHTON, Minn.--(BUSINESS WIRE)
Completes Second Year of Field Trials of its High Oleic Soybean Product NEW BRIGHTON, Minn.--(BUSINESS WIRE)--November 2, 2015--Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products to benefit both consumers and farmers, today announced that it
Read more →CLLSCalyxt Completes the First Field Trials of Its Cold Storable Potato Product NEW BRIGHTON, Minn.--(BUSINESS WIRE)
Completes the First Field Trials of Its Cold Storable Potato Product NEW BRIGHTON, Minn.--(BUSINESS WIRE)--November 2, 2015--Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products to benefit both consumers and farmers, today announced that it ha
Read more →CLLSSuccessful GMP Production Process for UCART19 NEW YORK--(BUSINESS WIRE)
GMP Production Process for UCART19 NEW YORK--(BUSINESS WIRE)--October 28, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS) today announced that a series of three production runs of UCART19, its lead TALEN gene edited product candi
Read more →CLLSCellectis Reports Second Quarter and First Half Year 2015 Financial Results PARIS--(BUSINESS WIRE)
Reports Second Quarter and First Half Year 2015 Financial Results PARIS--(BUSINESS WIRE)--September 8, 2015--Regulatory News: Cellectis S.A. (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (U
Read more →CLLSPRELIMINARY NOTE The unaudited half-year consolidated Financial Statements included herein have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Account
The unaudited half-year consolidated Financial Statements included herein have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The consolidated financial statements are pres
Read more →CLLSMD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy NEW YORK--(BUSINESS WIRE)
Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy NEW YORK--(BUSINESS WIRE)--September 3, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq: CLLS), the gene editing c
Read more →CLLSCellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies NEW YORK--(BUSINESS WIRE)
Announces Publication of an Article in Cancer on Allogeneic CAR T-cell Immunotherapies NEW YORK--(BUSINESS WIRE)--July 16, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS), the gene-editing company employing propriet
Read more →CLLSCellectis Reaches Milestone in Servier Collaboration NEW YORK--(BUSINESS WIRE)
Reaches Milestone in Servier Collaboration NEW YORK--(BUSINESS WIRE)--July 8, 2015--Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS), the gene-editing company employing proprietary technologies to develop best-in-class CAR
Read more →CLLSCalyxt Launches Field Trials of its Cold Storable Potato NEW BRIGHTON, Minn.--(BUSINESS WIRE)
Launches Field Trials of its Cold Storable Potato NEW BRIGHTON, Minn.--(BUSINESS WIRE)--July 8, 2015--Calyxt, Inc., a Minnesota-based company focusing on developing healthier food products, today announced that it has started the field trials of its cold Calyxt has previously
Read more →CLLSCellectis Reports First Quarter 2015 Financial Results PARIS--(BUSINESS WIRE)
Reports First Quarter 2015 Financial Results PARIS--(BUSINESS WIRE)--June 9, 2015--Regulatory News: Cellectis (Alternext: ALCLS - Nasdaq Global Market: CLLS), in order to comply with NASDAQ financial practices, is publishing for the first time its 1st quarter results. Cellec
Read more →CLLSWeill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia Collaboration Will Focus on Improving Patient Outcomes in AML Using
Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Will Focus on Improving Patient Outcomes in AML Using Targeted Cellular Therapy Developed by Cellectis NEW YORK--(BUSINESS WIRE)--June 2,
Read more →CLLSCellectis SA Combined General Shareholders' Meeting of
SA Combined General Shareholders' Meeting of May 18, 2015 PARIS--(BUSINESS WIRE)--May 19, 2015--Regulatory News: The Combined General Shareholders' Meeting of Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS) was held on Monday, May 18, 2015 in Pari
Read more →CLLSCellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)
S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting NEW YORK--(BUSINESS WIRE)--May 7, 2015--Regulatory News: Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS), a pioneering gene-editin
Read more →CLLSCellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary PARIS--(BUSINESS WIRE)
S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary PARIS--(BUSINESS WIRE)--May 4, 2015--Regulatory News: Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS - Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to devel
Read more →CLLSCELLECTIS A Soci t Anonyme with a share capital of 1,751,443.70 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris Trade & Companies Register (RCS) 428 859 052
Soci t Anonyme with a share capital of 1,751,443.70 Registered Office: 8, rue de la Croix Jarry - 75013 Paris Paris Trade & Companies Register (RCS) 428 859 052 As a shareholder of Cellectis, you are hereby invited to the Combined Ordinary and Extraordinary General Meeting to
Read more →CLLSCellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants Cellectis plant sciences entered in an exclusive license agreement with Regents of the University of Minnesota covering certain uses
Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in plant sciences entered in an exclusive license agreement with Regents of the University of Minnesota covering certain uses of CRISPR technology NEW BRIGHTON, Minn.--(BUSINESS WIRE)--April 15, 2015--Regulator
Read more →CLLSCellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes
Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes April 14, 2015 New Brighton (Minnesota, USA) Cellectis Plant Sciences, Inc. a Minnesota-based company focusing on developing healthier food products, has announced today that th
Read more →CLLSCellectis SA (Nasdaq: CLLS) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Mar. 25, 2015 (GLOBE NEWSWIRE) -- Cellectis SA (Nasdaq:CLLS), a pioneering gene-editing company focused on developing immunotherapies, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO), which will occur today, March 25
Read more →CLLSCellectis Acquires Exclusive License to Tal Effector Patents From University of Minnesota
PARIS, Jan. 20, 2011 (GLOBE NEWSWIRE) -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions rela
Read more →CLLSCellectis Grants Harvard Bioscience a License to CytoPulse Electroporation Instruments
PARIS and HOLLISTON, Mass., Dec. 2, 2010 (GLOBE NEWSWIRE) -- Cellectis (Alternext:ALCLS), the French genome engineering specialist, and Harvard Apparatus, a division of Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tool
Read more →Competitive Position
How CLLS ranks across every disease it competes inCompetitive Position is a premium feature
See how CLLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial